猪链球菌2型ECE1的致病性及6PGD蛋白的免疫原性研究
|
摘要
猪链球菌病由猪链球菌(Strreptococcus suis)引起的一种重要细菌性传染病。猪链球菌根据荚膜抗原成分的不同,分为33个血清型。其中猪链球菌2型(Strreptococcus suis serotype 2, SS2)作为一种重要人畜共患传染病,’不仅影响着养猪业健康发展,还严重危害着人类的健康。1998年夏季江苏省暴发了人感染2型猪链球菌病,14人死亡。2005年夏季,在四川省资阳市,暴发了人感染猪链球菌病,204人发病,38人死亡。
随着猪链球菌2型对养殖业和人类健康危害的日益加剧,最近几年其已成为国内外研究的热点,尤其是关于其致病与免疫机理方面的研究。致病机理方面的研究主要是集中在毒力因子发掘与功能鉴定以及引起脑膜炎的机制。虽然取得了一定的进展,但是仍然有许多问题没有阐明清楚,尤其是毒力因子之间的相互作用调控网络与细菌致病机理方面的相关性等问题。细菌的双组分调控系统(Two-Component Signal Transduction System, TCSTS)在细菌感受外界环境变化,调节自身基因表达方面发挥着重要作用。随着我国猪链球2型05ZYH33和98HAH12菌株全基因组测序的完成,目前已经有15对双组分调控系统被成功鉴定。本实验室构建了其中一对1660hk/rr新型双组分调控系统基因缺失突变株,通过体内外试验证实该双组分调控系统与猪链球菌2型致病性相关。进一步对一些已报道的重要毒力因子进行了荧光定量PCR验证,证实了研究结果的可靠性。然而,关于1660hk/rr双组分调控系统基因缺失后引起细菌致病性下降的分子机制尚不清楚。
鉴于以上背景,本课题在前期构建的1660hk/rr双组分调控系统基因缺失突变株基础上,通过基因表达谱芯片,研究了1660hk/rr基因缺失突变株的基因表达情况,结果显示除缺失目的基因外共有249个基因表达发生了变化。其中SSU05_0153基因下调倍数最大,通过BLAST发现SSU05_0153基因编码内皮素转化酶1(ecel),与真核生物的内皮素转换酶具有较高的同源性。ecel基因对调节生物体内皮素(ET)的生物学活性起着非常重要的作用。大量研究证实内皮素系统代谢功能紊乱与高血压、脂质代谢紊乱、糖尿病及动脉粥样硬化等大量疾病有关。通过构建猪链球菌2型ecel基因缺失突变株,经过体外生物学特性和动物体内毒力试验,研究ecel基因与毒力的关系。
当前,猪用商品化链球菌疫苗主要是灭活疫苗和弱毒疫苗。灭活疫苗副反应大,另外对其它血清型交叉免疫保护率不高。而使用的C群链球菌弱毒疫苗自然致弱,存在毒力返强的风险。因此,寻找新的疫苗抗原,研制新型安全、高效猪链球菌2型基因工程疫苗显得尤为重要。通过生物信息学分析和同源性比对,发现6-磷酸葡萄糖脱氢酶(6PGD)基因在多种细菌中非常保守,且文献已经报道肺炎链球菌的6PGD对小鼠能提供40%的免疫保护。因此,本课题以猪链球菌2型SC19菌株为材料,克隆表达了SS2的6-磷酸葡萄糖脱氢酶,开展了其体外活性和免疫原性研究。
论文主要研究内容包括：1.双组分调控系统1660hk/rr基因缺失突变株与野毒株的差异表达基因分析
根据Geenbank公布的SS2菌株05ZYH33全基因组序列,定制了SS2全基因组表达谱芯片,比较双组分调控系统1660hk/rr基因缺失突变株与野生菌株之间的差异表达基因。结果显示,有89个基因表达下调了2倍以上,其中25个基因下调表达5倍以上；上调2倍以上41个基因中有4个上调了5倍以上。为了获得更多信息,我们进一步统计了差异表达在1.5倍以上的基因。结果有152个基因下调,99个基因上调,占总基因数的11.4%。通过基因变化倍数以及生物信息学分析,我们推测05SSU0153基因(ecel)可能与猪链球菌2型致病性相关。
2.ecel基因缺失突变株的构建
根据Genbank中公布的SS2的ecel基因即05SSU0153的序列,以SC19菌株DNA为模板,分别克隆ecel基因上游1034bp和下游1041bp并连接到pMD18T载体,构建克隆载体pMD18T-PS和pMD18T-PX。然后逐步用HindⅢ与SalⅠ、SalⅠ与EcoR I酶切pMD18T-PS和pMD18T-PX,同时逐步用同样酶切的自杀性载体pSET4s,两次连接之后得到自杀性质粒pSET4s-0153。将构建好的自杀性重组转移质粒pSET4s-0153电转化到SS2野生菌株SC19中,通过抗生素和温度双重特征筛选,获得05SSU0153基因缺失菌株,命名Δ0153。通过PCR和测序进一步对基因缺失突变菌株进行了鉴定,结果表明突变株构建正确。
3.突变株生物学特性的研究
将SS2的ecel基因缺失突变株Δ0153在体外连续传代培养,通过PCR鉴定,证明该缺失菌株能够稳定遗传。在液体培养基中培养A0153基因缺失菌株与SS2野生菌株SC19,每小时取样测定菌液吸光值,根据结果绘制生长曲线,结果表明,A0153基因缺失突变株的增殖能力没有发生明显变化,说明ecel基因的缺失对SS2的体外增殖能力无影响。
4.突变株对仔猪的致病性
将SS2野生菌株SC19与突变株A0153以5×105cfu/ml,1×106cfu/ml和5×106cfu/ml的剂量,通过耳静脉(1m1)分别感染断奶仔猪。感染后每天观察记录仔猪临床症状,记录死亡情况,并通过病理解剖以及组织切片来评价不同菌株致病性的差异。结果显示突变株A0153攻毒后与野生菌株SC19相比,各不同剂量攻毒组临床症状较轻,死亡率显著降低。表明基因缺失突变株Δ0153对仔猪的致病力明显低于野生菌株SC19。
5.6PGD蛋白的克隆表达及细菌黏附抑制试验
根据Genbank中公布的SS2的6pgd基因序列,设计引物扩增该基因并连接到原核表达载体pET-28a上。将其转化到大肠杆菌表达菌株BL21(DE3),经IPTG诱导,得到重组蛋白6PGD,用组氨酸纯化试剂柱纯化。通过Western blot鉴定证实其具有反应原性。重组的6PGD蛋白与Hep2和HeLa细胞相互作用,阳性对照组不加蛋白作用,2小时后,所有试验组加入SS2野生菌株与细胞相互作用。结果显示加入蛋白后SS2对Hep2和HeLa细胞的黏附分别减少了72%和66%。表明6PGD能抑制SC19与细胞的黏附。
6.6PGD蛋白对小鼠的免疫保护试验
将20只6周龄Balb/C雌鼠,随机分成2组,每组10只。第1组免疫100μL完全弗氏佐剂乳化20μg6PGD蛋白,第2组免疫100μL完全弗氏佐剂为对照组,首免后14d,28d分别进行后二免和三免,剂量和方式同首免。但改为用不完全弗氏佐剂代替完全弗氏佐剂乳化。三免后10d所有小鼠用2.5×108 CFU (0.2mL)的SC19通过腹腔攻毒。一免前、二免前、三免前以及攻毒前,对小鼠尾静脉负压采血,检测血清抗体效价。攻毒后每天观察并记录小鼠的临床表现和死亡情况。结果显示：重组6PGD蛋白免疫小鼠14天可检测到特异性的抗体,在38天时抗体效价达到较高水平。攻毒后接种佐剂对照组小鼠表现出明显的临床症状,48h内全部死亡,解剖后发现多脏器有出血,从各脏器均能分离到攻毒用菌株。而6PGD蛋白免疫组攻毒后最终80%的免疫小鼠得到保护。攻毒后部分小鼠表现出临床症状。存活小鼠解剖后无明显病理变化,从脏器中不能分离到攻毒用野毒菌株。
7.6PGD蛋白对仔猪的免疫保护试验
将20头4周龄仔猪随机分成2个试验组,第1组每头肌肉注射500μL完全弗式佐剂乳化500μg6PGD蛋白,第2组每头注射500μL完全弗氏佐剂为对照组,两周后进行二免,二免的剂量和方式与同一免相同。用不完全弗氏佐剂代替完全弗氏佐剂。二免两周后用1.0×106 CFU(1mL)的SC19通过静脉攻毒。一免前、二免前和攻毒前对每头猪前腔静脉采血,用ELISA检测血清抗体效价。攻毒后的7天内每天观察临床症状。之后处死存活猪,观察病理变化,取组织作病理切片。结果显示重组蛋白免疫组猪14天可检测到特异性的抗体,在28天时抗体效价达到较高水平。攻毒后接种佐剂对照组猪在攻毒后表现明显的临床症状,48h内全部死亡解剖后发现多脏器有充血、出血,从各脏器均能分离到攻毒用菌株。而6PGD蛋白免疫组攻毒后大部分表现临床症状,部分症状较重,48h内死亡20%,部分猪逐渐好转,最终有50%的猪存活。存活猪,大部分脏器中不能分离到攻毒用野毒菌株。
Streptococcus suis is an important swine pathogen and 33 S. suis serotypes have been identified based on differences in their capsular antigens. S. suis serotype 2 (S. suis 2 or SS2) is the most frequently isolated serotype worldwide and can cause meningitis, septicemia, arthritis, endocarditis, pneumonia and even acute death in swine. In addition to causing disease in pigs, it is also an important zoonotic agent for humans in contact with diseased pigs or their products. In 1998, SS2 outbreaks in humans in Jiangsu, China infected 25 people of which 14 died. Between July and August 2005, an outbreak of SS2 infection occurred in Sichuan, China, involving 204 cases, of whom 38 died.
Due to high economic losses as well as threat to human life, the study of SS2 pathogenesis and the development of new vaccines is crucial for prevention and control of this disease. In this study, a micorarray was used to detect the differences in gene expression of a SS2 two component signal transduction (TCTS) 1660hk/rr gene deletion mutant and the wild type organism. Results show that totally 249 genes had differential expression patterns. The Endothelin-converting enzyme 1 gene (ecel) was found to be the most downregulated. The ecel gene deletion mutan was constructed by a homologous recombination based method. In vitro and in vivo data demonstrates that the ecel deletion mutan was attenuated. In order to find an effective subunit vaccine the 6-phosphogluconate-dehydrogenase (6pgd) was cloned and expressed. Sequencing this gene found that it has high similarity at the nucleotide level with other bacterial, for example the S. pneumoniae. The recombinant 6PGD protein inhibits the SS2 adhesion to host cells. Immunising animals with the recombinant 6PGD protein provided 80% and 50% protection of mice and swines respectively against SS2 high virulence strain infection. The main research contents include:
1. Gene different expression of 1660hk/rr deleted mutant strain
In this study we used a microarry which was made by using available the SS2 05ZYH33 strain whole genome sequence. To compare with the wild type SS2 strain SC19 gene expression, the TCTS 1660hk/rr gene deletion mutant shows that 89 genes were down-regulated 2-fold and 41 genes were upregulated 2-fold. Of the 89 genes,25 were downregulated more than 5 fold and 4 were upregulated to the same level. In order to obtain more information, we altered the cut off gene expression change level to 1.5 times. In total 152 genes were down regulated and 99 were upregulated accounting for 11.4% of all the ORFs within the SS2 genome.
2. Construction of ecel mutant
Primers were designed to amplify 1034bp of the ecel gene upstream and 1041bp of the downstream sequence based on the SS2 strain 05SSU0153 ecel gene sequence. The two PCR products were purified and cloned into a pMD18T vector resulting in the construction of pMD18T-PS and pMD18T-PX. pMD18T-PS was digested with HindⅢand Sal I, pMD18T-PX digested with Sal I and EcoR I. The suicide vector pSET4s was digested with the same enzymes gradually, after the ligation was completea suicide plasmid, pSET4s-0153 was obtained. The resulting suicide recombinant plasmid pSET4s-0153 was transformed by electroporation into the SS2 wild strain SC19. Through a double feature selection of antibiotics and temperature, the 05SSU0153 gene deletion mutant strain was obtained and namedΔ0153. The gene deletion mutant was confirmed by PCR
3. Characterization of the SS2 mutants
Heredity and stability of the SS2 ecel gene deleted mutantΔ0153 was confirmed by continuous passage culture and PCR this confirmed that the mutation was stable. The growth rate of the ece1 deletion mutant was compared to the wild type strain SC19 by measuring OD600 at different time points. The results indicated no difference between parent strain SC19 and mutant strainΔ0153.
4. Virulence in pigs
In order to test the virulence capacity of mutant strainΔ0153, pigs were intravenously infected with three different doses 5×105cfu/ml, 1×106cfu/ml and 5×106cfu/ml of wildtype (SC19) and mutant strainΔ0153. Clinical symptoms and survival were observed and recorded daily after the initial infection. The pathological anatomy and pathology were also used to evaluate the virulence of different strains of SS2. The results showed that compared with wildtype strain SC19, mutant strainΔ0153 post-infection showed mild clinical symptoms of disease and the death rate decreased significantly. All these results suggested the mutant strain A0153 significantly attenuated when compared to the wildtype strain SC19.
5. Expression 6PGD protein and the bacterial inhibition test
The 6pgd gene of SS2 was amplified by PCR withprimers designed according to the published Genbank SS2 6pgd gene sequence and cloned to the expression vector pET-28. The plasmid was transformed into E. coli expression strain BL21 (DE3) and induced by IPTG. Recombinant 6PGD protein was isolated using histidine purification reagents and confirmed by western blot. The ability of the 6PGD protein to inhibit SS2 virulence by monitoring adhesion to host Hep2 and HeLa cells was tested. The results showed that after adding the 6PGD protein, SS2 adhesion to Hep2 and HeLa cells was decreased by about 72% and 66%. This may indicate that 6PGD protein may play as an adhesion factor in SS2.
6. 6PGD protein protection in mice
Twenty 6-week-old Balb/c female mice were randomly divided into two experimental groups of ten to evaluate the efficacy of the 6PGD protein as a subunit vaccine. Group one was immunized subcutaneously with 20 mg of purified r6PGD mixed with 100 mL complete Freund's Adjuvant on day 0 (primary immunization). At days 14 and 28, the mice were immunized with 20 mg of r6PGD protein emulsified with 100 mL incomplete Freund's Adjuvant according to the manufacturer's protocol. The other group was immunized subcutaneously with adjuvant as a control. Ten days after the third vaccination, the animals from both groups were challenged intraperitoneally with 2.5×108 CFU per mouse of log-phase SS2 virulence strain SC19 in 0.2 mL TSB. Mice were bled at days 0,14,28 and 38, serum samples were detected by 6PGD ELISA. Clinical symptoms and survival were monitored daily after infection. The results showed that anti-6PGDantibody can be detected at day 14 and that on day 38 the specific antibody reaches a higher level. After infection, the adjuvant control mice showed significant clinical symptoms and all died in 48h. Anatomicallymultiple organ bleeding was noted and SS2 could beisolated from various organs. Some of the 6PGD protein immunized group mice showed clinical symptoms of disease but finally 80% were protected. Afternatomical examination of the surviving mice, no significant changes could be observed and the challenge organismcould not be isolated from organs.
7. 6PGD protein protection in pigs
Twenty 4-week-old pigs were taken from a herd that was SS2 free and were randomly assigned to two groups of 10 pigs each. Group one were immunized intramuscularly with 500 mg of purified 6PGD mixed with 500 mL complete Freund's adjuvant on day 0. At day 14, the pigs were immunized with 500 mg 6PGD emulsified with 500 mL incomplete Freund's adjuvant, according to the manufacturer's protocol. The other group was immunized with only the adjuvant as the control group. Two weeks after the booster immunization, all twenty pigs in both immunizedcontrolgroups were intravenously challenged with 1×106 CFU per pig of a log-phase culture of SS2 virulence strain SC19 in 1 mL TSB. On days 0,14, and 28, blood samples were obtained from each pig by precaval vein bleeding and serum samples were detected by 6PGD ELISA. Clinical symptoms and survival were monitored daily after infection. After 7 days observation, all the surviving pigs were killed to observe the pathological changes in the organs and also take the tissues for pathology studies. The results showed that the anti-6PGD protein specific antibody could be detected on day 14 and that on day 28 the antibody reaches a higher level. After infection, the adjuvant control pigs showed significant clinical symptoms and all died at 48h. Anatomically the animals were foundto have multiple organs with hyperemia, hemorrhage and the challenge organism could be isolated from various organs. In the 6PGD protein immunized group, some pigs had significant clinical symptoms and 20% died within 48h. Finally,50% of the immunized pigs were protected. After anatomical examination of the surviving pigs, most of the organs did not contain culturable SS2.
随着猪链球菌2型对养殖业和人类健康危害的日益加剧,最近几年其已成为国内外研究的热点,尤其是关于其致病与免疫机理方面的研究。致病机理方面的研究主要是集中在毒力因子发掘与功能鉴定以及引起脑膜炎的机制。虽然取得了一定的进展,但是仍然有许多问题没有阐明清楚,尤其是毒力因子之间的相互作用调控网络与细菌致病机理方面的相关性等问题。细菌的双组分调控系统(Two-Component Signal Transduction System, TCSTS)在细菌感受外界环境变化,调节自身基因表达方面发挥着重要作用。随着我国猪链球2型05ZYH33和98HAH12菌株全基因组测序的完成,目前已经有15对双组分调控系统被成功鉴定。本实验室构建了其中一对1660hk/rr新型双组分调控系统基因缺失突变株,通过体内外试验证实该双组分调控系统与猪链球菌2型致病性相关。进一步对一些已报道的重要毒力因子进行了荧光定量PCR验证,证实了研究结果的可靠性。然而,关于1660hk/rr双组分调控系统基因缺失后引起细菌致病性下降的分子机制尚不清楚。
鉴于以上背景,本课题在前期构建的1660hk/rr双组分调控系统基因缺失突变株基础上,通过基因表达谱芯片,研究了1660hk/rr基因缺失突变株的基因表达情况,结果显示除缺失目的基因外共有249个基因表达发生了变化。其中SSU05_0153基因下调倍数最大,通过BLAST发现SSU05_0153基因编码内皮素转化酶1(ecel),与真核生物的内皮素转换酶具有较高的同源性。ecel基因对调节生物体内皮素(ET)的生物学活性起着非常重要的作用。大量研究证实内皮素系统代谢功能紊乱与高血压、脂质代谢紊乱、糖尿病及动脉粥样硬化等大量疾病有关。通过构建猪链球菌2型ecel基因缺失突变株,经过体外生物学特性和动物体内毒力试验,研究ecel基因与毒力的关系。
当前,猪用商品化链球菌疫苗主要是灭活疫苗和弱毒疫苗。灭活疫苗副反应大,另外对其它血清型交叉免疫保护率不高。而使用的C群链球菌弱毒疫苗自然致弱,存在毒力返强的风险。因此,寻找新的疫苗抗原,研制新型安全、高效猪链球菌2型基因工程疫苗显得尤为重要。通过生物信息学分析和同源性比对,发现6-磷酸葡萄糖脱氢酶(6PGD)基因在多种细菌中非常保守,且文献已经报道肺炎链球菌的6PGD对小鼠能提供40%的免疫保护。因此,本课题以猪链球菌2型SC19菌株为材料,克隆表达了SS2的6-磷酸葡萄糖脱氢酶,开展了其体外活性和免疫原性研究。
论文主要研究内容包括：1.双组分调控系统1660hk/rr基因缺失突变株与野毒株的差异表达基因分析
根据Geenbank公布的SS2菌株05ZYH33全基因组序列,定制了SS2全基因组表达谱芯片,比较双组分调控系统1660hk/rr基因缺失突变株与野生菌株之间的差异表达基因。结果显示,有89个基因表达下调了2倍以上,其中25个基因下调表达5倍以上；上调2倍以上41个基因中有4个上调了5倍以上。为了获得更多信息,我们进一步统计了差异表达在1.5倍以上的基因。结果有152个基因下调,99个基因上调,占总基因数的11.4%。通过基因变化倍数以及生物信息学分析,我们推测05SSU0153基因(ecel)可能与猪链球菌2型致病性相关。
2.ecel基因缺失突变株的构建
根据Genbank中公布的SS2的ecel基因即05SSU0153的序列,以SC19菌株DNA为模板,分别克隆ecel基因上游1034bp和下游1041bp并连接到pMD18T载体,构建克隆载体pMD18T-PS和pMD18T-PX。然后逐步用HindⅢ与SalⅠ、SalⅠ与EcoR I酶切pMD18T-PS和pMD18T-PX,同时逐步用同样酶切的自杀性载体pSET4s,两次连接之后得到自杀性质粒pSET4s-0153。将构建好的自杀性重组转移质粒pSET4s-0153电转化到SS2野生菌株SC19中,通过抗生素和温度双重特征筛选,获得05SSU0153基因缺失菌株,命名Δ0153。通过PCR和测序进一步对基因缺失突变菌株进行了鉴定,结果表明突变株构建正确。
3.突变株生物学特性的研究
将SS2的ecel基因缺失突变株Δ0153在体外连续传代培养,通过PCR鉴定,证明该缺失菌株能够稳定遗传。在液体培养基中培养A0153基因缺失菌株与SS2野生菌株SC19,每小时取样测定菌液吸光值,根据结果绘制生长曲线,结果表明,A0153基因缺失突变株的增殖能力没有发生明显变化,说明ecel基因的缺失对SS2的体外增殖能力无影响。
4.突变株对仔猪的致病性
将SS2野生菌株SC19与突变株A0153以5×105cfu/ml,1×106cfu/ml和5×106cfu/ml的剂量,通过耳静脉(1m1)分别感染断奶仔猪。感染后每天观察记录仔猪临床症状,记录死亡情况,并通过病理解剖以及组织切片来评价不同菌株致病性的差异。结果显示突变株A0153攻毒后与野生菌株SC19相比,各不同剂量攻毒组临床症状较轻,死亡率显著降低。表明基因缺失突变株Δ0153对仔猪的致病力明显低于野生菌株SC19。
5.6PGD蛋白的克隆表达及细菌黏附抑制试验
根据Genbank中公布的SS2的6pgd基因序列,设计引物扩增该基因并连接到原核表达载体pET-28a上。将其转化到大肠杆菌表达菌株BL21(DE3),经IPTG诱导,得到重组蛋白6PGD,用组氨酸纯化试剂柱纯化。通过Western blot鉴定证实其具有反应原性。重组的6PGD蛋白与Hep2和HeLa细胞相互作用,阳性对照组不加蛋白作用,2小时后,所有试验组加入SS2野生菌株与细胞相互作用。结果显示加入蛋白后SS2对Hep2和HeLa细胞的黏附分别减少了72%和66%。表明6PGD能抑制SC19与细胞的黏附。
6.6PGD蛋白对小鼠的免疫保护试验
将20只6周龄Balb/C雌鼠,随机分成2组,每组10只。第1组免疫100μL完全弗氏佐剂乳化20μg6PGD蛋白,第2组免疫100μL完全弗氏佐剂为对照组,首免后14d,28d分别进行后二免和三免,剂量和方式同首免。但改为用不完全弗氏佐剂代替完全弗氏佐剂乳化。三免后10d所有小鼠用2.5×108 CFU (0.2mL)的SC19通过腹腔攻毒。一免前、二免前、三免前以及攻毒前,对小鼠尾静脉负压采血,检测血清抗体效价。攻毒后每天观察并记录小鼠的临床表现和死亡情况。结果显示：重组6PGD蛋白免疫小鼠14天可检测到特异性的抗体,在38天时抗体效价达到较高水平。攻毒后接种佐剂对照组小鼠表现出明显的临床症状,48h内全部死亡,解剖后发现多脏器有出血,从各脏器均能分离到攻毒用菌株。而6PGD蛋白免疫组攻毒后最终80%的免疫小鼠得到保护。攻毒后部分小鼠表现出临床症状。存活小鼠解剖后无明显病理变化,从脏器中不能分离到攻毒用野毒菌株。
7.6PGD蛋白对仔猪的免疫保护试验
将20头4周龄仔猪随机分成2个试验组,第1组每头肌肉注射500μL完全弗式佐剂乳化500μg6PGD蛋白,第2组每头注射500μL完全弗氏佐剂为对照组,两周后进行二免,二免的剂量和方式与同一免相同。用不完全弗氏佐剂代替完全弗氏佐剂。二免两周后用1.0×106 CFU(1mL)的SC19通过静脉攻毒。一免前、二免前和攻毒前对每头猪前腔静脉采血,用ELISA检测血清抗体效价。攻毒后的7天内每天观察临床症状。之后处死存活猪,观察病理变化,取组织作病理切片。结果显示重组蛋白免疫组猪14天可检测到特异性的抗体,在28天时抗体效价达到较高水平。攻毒后接种佐剂对照组猪在攻毒后表现明显的临床症状,48h内全部死亡解剖后发现多脏器有充血、出血,从各脏器均能分离到攻毒用菌株。而6PGD蛋白免疫组攻毒后大部分表现临床症状,部分症状较重,48h内死亡20%,部分猪逐渐好转,最终有50%的猪存活。存活猪,大部分脏器中不能分离到攻毒用野毒菌株。
Streptococcus suis is an important swine pathogen and 33 S. suis serotypes have been identified based on differences in their capsular antigens. S. suis serotype 2 (S. suis 2 or SS2) is the most frequently isolated serotype worldwide and can cause meningitis, septicemia, arthritis, endocarditis, pneumonia and even acute death in swine. In addition to causing disease in pigs, it is also an important zoonotic agent for humans in contact with diseased pigs or their products. In 1998, SS2 outbreaks in humans in Jiangsu, China infected 25 people of which 14 died. Between July and August 2005, an outbreak of SS2 infection occurred in Sichuan, China, involving 204 cases, of whom 38 died.
Due to high economic losses as well as threat to human life, the study of SS2 pathogenesis and the development of new vaccines is crucial for prevention and control of this disease. In this study, a micorarray was used to detect the differences in gene expression of a SS2 two component signal transduction (TCTS) 1660hk/rr gene deletion mutant and the wild type organism. Results show that totally 249 genes had differential expression patterns. The Endothelin-converting enzyme 1 gene (ecel) was found to be the most downregulated. The ecel gene deletion mutan was constructed by a homologous recombination based method. In vitro and in vivo data demonstrates that the ecel deletion mutan was attenuated. In order to find an effective subunit vaccine the 6-phosphogluconate-dehydrogenase (6pgd) was cloned and expressed. Sequencing this gene found that it has high similarity at the nucleotide level with other bacterial, for example the S. pneumoniae. The recombinant 6PGD protein inhibits the SS2 adhesion to host cells. Immunising animals with the recombinant 6PGD protein provided 80% and 50% protection of mice and swines respectively against SS2 high virulence strain infection. The main research contents include:
1. Gene different expression of 1660hk/rr deleted mutant strain
In this study we used a microarry which was made by using available the SS2 05ZYH33 strain whole genome sequence. To compare with the wild type SS2 strain SC19 gene expression, the TCTS 1660hk/rr gene deletion mutant shows that 89 genes were down-regulated 2-fold and 41 genes were upregulated 2-fold. Of the 89 genes,25 were downregulated more than 5 fold and 4 were upregulated to the same level. In order to obtain more information, we altered the cut off gene expression change level to 1.5 times. In total 152 genes were down regulated and 99 were upregulated accounting for 11.4% of all the ORFs within the SS2 genome.
2. Construction of ecel mutant
Primers were designed to amplify 1034bp of the ecel gene upstream and 1041bp of the downstream sequence based on the SS2 strain 05SSU0153 ecel gene sequence. The two PCR products were purified and cloned into a pMD18T vector resulting in the construction of pMD18T-PS and pMD18T-PX. pMD18T-PS was digested with HindⅢand Sal I, pMD18T-PX digested with Sal I and EcoR I. The suicide vector pSET4s was digested with the same enzymes gradually, after the ligation was completea suicide plasmid, pSET4s-0153 was obtained. The resulting suicide recombinant plasmid pSET4s-0153 was transformed by electroporation into the SS2 wild strain SC19. Through a double feature selection of antibiotics and temperature, the 05SSU0153 gene deletion mutant strain was obtained and namedΔ0153. The gene deletion mutant was confirmed by PCR
3. Characterization of the SS2 mutants
Heredity and stability of the SS2 ecel gene deleted mutantΔ0153 was confirmed by continuous passage culture and PCR this confirmed that the mutation was stable. The growth rate of the ece1 deletion mutant was compared to the wild type strain SC19 by measuring OD600 at different time points. The results indicated no difference between parent strain SC19 and mutant strainΔ0153.
4. Virulence in pigs
In order to test the virulence capacity of mutant strainΔ0153, pigs were intravenously infected with three different doses 5×105cfu/ml, 1×106cfu/ml and 5×106cfu/ml of wildtype (SC19) and mutant strainΔ0153. Clinical symptoms and survival were observed and recorded daily after the initial infection. The pathological anatomy and pathology were also used to evaluate the virulence of different strains of SS2. The results showed that compared with wildtype strain SC19, mutant strainΔ0153 post-infection showed mild clinical symptoms of disease and the death rate decreased significantly. All these results suggested the mutant strain A0153 significantly attenuated when compared to the wildtype strain SC19.
5. Expression 6PGD protein and the bacterial inhibition test
The 6pgd gene of SS2 was amplified by PCR withprimers designed according to the published Genbank SS2 6pgd gene sequence and cloned to the expression vector pET-28. The plasmid was transformed into E. coli expression strain BL21 (DE3) and induced by IPTG. Recombinant 6PGD protein was isolated using histidine purification reagents and confirmed by western blot. The ability of the 6PGD protein to inhibit SS2 virulence by monitoring adhesion to host Hep2 and HeLa cells was tested. The results showed that after adding the 6PGD protein, SS2 adhesion to Hep2 and HeLa cells was decreased by about 72% and 66%. This may indicate that 6PGD protein may play as an adhesion factor in SS2.
6. 6PGD protein protection in mice
Twenty 6-week-old Balb/c female mice were randomly divided into two experimental groups of ten to evaluate the efficacy of the 6PGD protein as a subunit vaccine. Group one was immunized subcutaneously with 20 mg of purified r6PGD mixed with 100 mL complete Freund's Adjuvant on day 0 (primary immunization). At days 14 and 28, the mice were immunized with 20 mg of r6PGD protein emulsified with 100 mL incomplete Freund's Adjuvant according to the manufacturer's protocol. The other group was immunized subcutaneously with adjuvant as a control. Ten days after the third vaccination, the animals from both groups were challenged intraperitoneally with 2.5×108 CFU per mouse of log-phase SS2 virulence strain SC19 in 0.2 mL TSB. Mice were bled at days 0,14,28 and 38, serum samples were detected by 6PGD ELISA. Clinical symptoms and survival were monitored daily after infection. The results showed that anti-6PGDantibody can be detected at day 14 and that on day 38 the specific antibody reaches a higher level. After infection, the adjuvant control mice showed significant clinical symptoms and all died in 48h. Anatomicallymultiple organ bleeding was noted and SS2 could beisolated from various organs. Some of the 6PGD protein immunized group mice showed clinical symptoms of disease but finally 80% were protected. Afternatomical examination of the surviving mice, no significant changes could be observed and the challenge organismcould not be isolated from organs.
7. 6PGD protein protection in pigs
Twenty 4-week-old pigs were taken from a herd that was SS2 free and were randomly assigned to two groups of 10 pigs each. Group one were immunized intramuscularly with 500 mg of purified 6PGD mixed with 500 mL complete Freund's adjuvant on day 0. At day 14, the pigs were immunized with 500 mg 6PGD emulsified with 500 mL incomplete Freund's adjuvant, according to the manufacturer's protocol. The other group was immunized with only the adjuvant as the control group. Two weeks after the booster immunization, all twenty pigs in both immunizedcontrolgroups were intravenously challenged with 1×106 CFU per pig of a log-phase culture of SS2 virulence strain SC19 in 1 mL TSB. On days 0,14, and 28, blood samples were obtained from each pig by precaval vein bleeding and serum samples were detected by 6PGD ELISA. Clinical symptoms and survival were monitored daily after infection. After 7 days observation, all the surviving pigs were killed to observe the pathological changes in the organs and also take the tissues for pathology studies. The results showed that the anti-6PGD protein specific antibody could be detected on day 14 and that on day 28 the antibody reaches a higher level. After infection, the adjuvant control pigs showed significant clinical symptoms and all died at 48h. Anatomically the animals were foundto have multiple organs with hyperemia, hemorrhage and the challenge organism could be isolated from various organs. In the 6PGD protein immunized group, some pigs had significant clinical symptoms and 20% died within 48h. Finally,50% of the immunized pigs were protected. After anatomical examination of the surviving pigs, most of the organs did not contain culturable SS2.
引文
1.拜廷阳,闫若潜,昊志明,普志乎,盛敏,杨增岐.猪链球菌病研究进展.动物医学进展,2007,28：83-87
2.程功,李明,郑峰,王晶,王长军,潘秀珍,范红结,唐家琪.Ⅱ型猪链球菌二元信号转导系统2148hk/rr基因敲除突变体的构建.微生物学通报,2008,35：25-29
3.狄晴,许利刚,张颖冬,曹辉.内皮素转换酶基因在急性脑梗死患者外周血中的表达及临床其意义.临床神经病学杂志,2007,20：92-94
4.董国英,李敏,向华.人畜共患新病原——猪链球菌2型的研究进展.广东畜牧兽医科技,2005,30：8-13
5.何孔旺,倪艳秀,王继春.猪链球菌2型的分子流行病学研究.中国人兽共患病杂志,2002,18：45-47
6.姜成刚,刘荻萩,蔡雪辉.猪链球菌2型对PK-15细胞的黏附动力学.中国畜牧兽医,2008,35：27-29
7.金冬雁,黎孟枫等译.J.萨姆布鲁克,EF弗里奇,T曼尼阿蒂斯著.分子克隆实验指南,第二版.科学出版社,1989.
8.李立虎.猪链球菌病的研究进展.畜牧与饲料科学,2009,30：173-174
9.李明,胡福泉,唐家琪.二元信号转导系统与细菌的致病性.微生物学杂志,2007,27：50-54
10.马有智,方维焕.猪链球菌血清2型JX02株溶血素基因的克隆及序列分析.中国兽医杂志,2003,23：460-462
11.莫才清,李阜棣,周俊初.原核生物细胞如何对环境因子作出响应、其信号传导路径及对逆境(非生物物质降解)的适应性.微生物学杂志,1997,17：41-46
12.邱全胜.双组分系统——细胞识别渗透胁迫信号的感应器.生物化学与生物物理进展,2000,27：593-596
13.沈艳,崔立,华修国.猪链球菌2型引起脑膜炎致病机制的研究进展.中国畜牧兽医,2007,34：92-94
14.孙理云,范红结,陆承平.猪链球菌2型FBPS的纤连蛋白结合部位的初步确定.微生物学报,2005,45：753-756
15.孙理云.猪链球菌2型与宿主细胞的相互作.中国人兽共患病学报,2008,24：775-776
16.唐家琪,朱进,郭恒彬,胡晓抒,朱凤才,刘光中.猪链球菌引起人中毒性休克综合征和脑膜脑炎的流行病学调查及病原学研究.第三军医大学学报,2001,23：1292-1295
17.魏武,丁国徽,王晓婧,孙景春,屠康,郝沛,王川,曹志伟,石铁流,李亦学.猪链球菌全基因组序列比较分析.科学通报,2006,51：808-818
18.吴德,罗会明,郑慧贞.人—猪链球菌病流行病学研究进展.中华流行病学杂志,2007,28：402-404
19.吴涛.猪链球菌2型revS基因缺失突变株的构建及其生物学特性研究和HYL蛋白与宿主蛋白质相互作用的研究.[博士学位论文].武汉：华中农业大学图书馆,2008
20.徐敏,蔡雪辉,王淑杰,刘永刚.猪链球菌2型毒力因子研究进展.动物医学进展,2009,30：65-70
21.杨俊兴.猪链球菌2型抗体检测试纸条的制备及FBPS与宿主蛋白质相互作用研究.[博士学位论文].武汉：华中农业大学图书馆,2007
22.杨维中,刘伦光,高永军,安向东,余宏杰,景怀琦,徐建国,陈志海,祝小平,汪华,刘学成,王世文,祖荣强,罗隆泽,向妮娟,刘红露,钟文君,刘莉,孟玲,袁珩,杜化茂等.四川省一起伴中毒性休克综合征的人感染猪链球菌2型暴发.中华流行病学杂志,2006,27：185-191
23.曾巧英,陆承平.猪链球菌2型对扁桃腺上皮细胞的黏附和侵袭作用.微生物学报,2004,44：523-525
24.曾巧英,陆承平.猪链球菌2型溶菌酶释放蛋白诱导上皮细胞融合和凋亡.微生物学报,2003,43：407-412
25.曾小涛,袁媛,郑玉玲,周冬生,姜永强,陈福生.猪链球菌2型全基因DNA芯片的研制及基因表达谱技术平台的建立.生物技术通讯,2009,658-661
26.查红波.2型猪链球菌病研究进展.江西饲料,2005,26：27-29
27.张安定,金梅林,陈焕春.猪链球菌2型研究进展(综述).养殖与饲料,2005,10：13-18
28.张淑伟,鲁成武.猪链球菌2型的致病机制.生命的化学,2006,26：178-180
29.郑继平,郭桂英,韦双双,周海龙,张兆山.猪链球菌2型疫苗研究进展.生物技术通讯,2005,17：826-828
30.周冬生,杨瑞馥.生物芯片分类及其技术原理.微生物学免疫学进展,2002a,30：101-107
31.周冬生,杨瑞馥.机械点样DNA微点阵技术及其在基因表达分析上的应用(Ⅰ).生物技术通讯,2002b,13：315-321
32.周冬生,杨瑞馥.机械点样DNA微点阵技术及其在基因表达分析上的应用(Ⅱ).生物技术通讯,2002c,13：408-414
33.朱进,唐家琪,张云,郭恒彬,陶开华.爆发流行中毒性休克综合征病原体生物学特性及鉴定.中华传染病杂志,2001,19：84-86
34.朱进,唐家琪,郭恒彬,张云,陶开华.一起猪链球菌病暴发流行的流行病学及病原学研究.解放军预防医学杂志,2000,18：257-260
35. Awano S, Ansai T, Mochizuki H, Yu W, Tanzawa K, Turner A J, Takehara T. Sequencing, expression and biochemical characterization of the Porphyromonas gingivalis pepO gene encoding a protein homologous to human endothelin-converting enzyme. FEBS Lett,1999,460:139-144
36. Allen A G, Bolitho S, Lindsay H, Khan S, Bryant C, Norton P, Ward P, Leigh J, Morgan J, Riches H, Eastty S, Maskell D. Generation and characterization of a defined mutant of Streptococcus suis lacking suilysin. Infect Immun,2001,69:2732-2735
37. Allgaier A, Goethe R, Wisselink H J, Smith H E, Valentin-Weigand P. Relatedness of Streptococcus suis Isolates of Various Serotypes and Clinical Backgrounds as Evaluated by Macrorestriction Analysis and Expression of Potential Virulence Traits, J Clin Microbiol,2001,39:445-453
38. Azuma R, Hara Y, Oonuma Y, Sugimoto C. Streptococcus R (Streptococcus suis type II) infection in pigs in Japan. National Institute of Animal Health Quarterly,1983, 23:117-126
39. Arends J P, Harwig N, Rudolphy M, Zanen H C. Carrier rate of Streptococcus suis capsular type 2 in palatine tonsils of slaughtered pigs. J Clin Microbiol,1984, 20:945-947
40. Allen A G, Lindsay H, Seilly D, Bolitho A, teters S E, Maskell D J. Identification and characterisation of hyaluronate lyase from Streptococcus suis. Microbial Pathogenesis,2004,36:327-335
41. Appleby J L, Parkinson J S, Bourret R B. Signal transduction via the multi-step phosphorelay:not necessarily a road less traveled. Cell,1996,86:845-848
42. Arends J P, Zanen H C. Meningitis caused by Streptococcus suis in humans. Rev Infect Dis,1988,10:131-137
43. Bajaj V, Lucas R L, Hwang C, Lee C A. Co-ordinate regulation of Salmonella typhimurium invasion genes by environmental and regulatory factors is mediated by control of hilA expression. Mol Microbiol.1996,22:703-714
44. Boetner A G., Binder M, Bille-Hansen V. Streptococcus suis infection in Danish pigs and experimental infection with Streptococcus suis serotype 7. Acta Pathol Microbiol Scand B,1987,95:233-239
45. Bourret R B, Borkovich K A, Simon M I. Signal transduction pathways involving protein phosphorylation in prokaryotes. Annu Rev Biochem,1991,60:401-441
46. Barrett J F, Goldschmidt R M, Lawrence L E, Foleno B, Chen R, Demers J P, Johnson S, Kanojia R, Fernandez J, Bernstein J, Licata L, Donetz A, Huang S, Hlasta D J, Macielag M J, Ohemeng K, Frechette R, Frosco M B, Klaubert D H, Whiteley J M, Wang L, Hoch J A. Antibacterial agents that inhibit two-component signal transduction systems. P Natl Acad Sci USA,1998a,95:5317-5322
47. Benga L, Fulde M, Neis C, Goethe R, Valentin-Weigand P. Polysaccharide capsule and suilysin contribute to extracellular survival of Streptococcus suis co-cultivated with primary porcine phagocytes. Vet Microbiol,2008,132:211-219
48. Beier D, Gross R. Regulation of bacterial virulence by two-component systems. Curr Opin Microbiol,2006,9:143-152
49. Barrett J F, Hoch J A. Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob Agents Chemother,1998b,42:1529-1536
50. Ba-Thein W, Lyristis M, Ohtani K, Nisbet IT, Hayashi H, et al. (1996) The virR/virS locus regulates the transcription of genes encoding extracellular toxin production in Clostridium perfringens. J Bacteriol 178:2514-2520
51. Baums C G, Kaim U, Fulde M, Ramachandran G, Goethe R, Valentin-Weigand P. Identification of a novel virulence determinant with serum opacification activity in Strptococcus suis. Infect Immun,2006,74:6154-6162
52. Berry A M, Lock R A, Thomas S M, Rajan D P, Hansman D, Paton J C. Cloning and nucleotide sequence of the Streptococcus pneumoniae hyaluronidase gene and purification of the enzyme from recombinant Escherichia coli. Infect Immun,1994, 62:1101-1108
53. Berthelot-Herault F, Morvan H, Keribin A M, Gottschalk M, Kobisch M. Production of muramidase released protein (MRP), extracellular factor (EF) and haemolysin by field isolates of Streptococcus suis capsular type 2,1/2,9,7 and 3 isolated from swine in France. Vet Res,2000,31:473-479
54. Bronner S, Monteil H, Pre'vost G. Regulation of virulence determinants in Staphylococcus aureus:complexity and applications. FEMS Microbiol Rev,2004, 28:183-200
55. Brown L N. Alpha hemolytic streptococci isolated from acute pneumonia and septicemia of Iowa swine. Proceedings of the Annual Meeting of the US Animal Health Association,1969,73:589-594
56. Busque P, Higgins R, Caya F, Quessy S. Immunisation of pigs against Streptococcus suis serotype 2 infection using a live avirulent strain. Can J Vet Res,1997,61:275-279
57. Barabote R D, Saier M H. Comparative genomic analyses of the bacterial phosphotransferase system. Microbiol Mol Biol Rev,2005,69:608-634
58. Baums C G, Valentin-Weigand P. Surface-assiociated and secreted factors of Streptococcus suis in epidemiology, pathogenesis and vaccine development. Animal Health Research Reviews,2009,20:65-83
59. Calvinho L F, Almeida R A, Oliver S P. Potential virulence factors of Streptococcus dysgalactiae associated with bovine mastitis. Vet Microbiol,1998; 61:93-110
60. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol,1992,62:S3-10
61. Chabot-Roya G, Willsonb P, Seguraa M, Lacouturea S, Gottschalk M. Phagocytosis and killing of Streptococcus suis by porcine neutrophils. Microbial Pathogenesis, 2006,41:21-32
62. Chang C, Stewart R C. The two-component system. Regulation of diverse signaling pathways in prokaryotes and eukaryotes. Plant Physiol,1998,117:723-31
63. Chanter N, Jones P W, Alexander T J L. Meningitis in pigs caused by Streptococcus suis-a speculative review. Vet Microbiol,1993,36:39-55
64. Charland N, Harel J, Kobisch M, Lacasse S, Gottschalk M. Streptococcus suis serotype 2 mutants deficient in capsular expression. Microbiology,1998,144:325-332
65. Charland N, Nizet V, Rubens C E, Kim K S, Lacouture S, Gottschalk M. Streptococcus suis serotype 2 interactions with human brain microvascular endothelial cells. Infect Immun,2000,68:637-643
66. Charland N, Kobisch M, Martineau-Doize B, Jacques M, Gottschalk M. Role of capsular sialic acid in virulence and resistance to phagocytosis of Streptococcus suis capsular type 2. FEMS Immunol Med Microbiol,1996,14:195-203
67. Chau P Y, Huang C Y, Kay R. Streptococcus suis meningitis. An important underdiagnosed disease in Hong Kong. Med J of Australia,1983,1:414-417
68. Chengappa M M, Pace L W, Williams J A, Herrin C H, Ascher S E. Efficacy of tiamulin against experimentally induced Streptococcus suis. J Am Vet Med Assoc, 1990,197:1467-1470.
69. Chengappa M M, Maddux R L, Kadel W L, Greer S C, Herren C E. Streptococcus suis infection in pigs:incidence and experimental reproduction of the syndrome. In: M.W. Vorhies (ed.), Proceedings of the American Association of Veterinary Laboratory Diagnosticians, Louisville,1986,29:25-38
70. Chen C, Tang J, Dong W, Wang C, Feng Y, Wang J, Zheng F, Pan X, Liu D, Li M, Song Y, Zhu X, Sun H, Feng T, Guo Z, Ju A, Ge J, Dong Y, Sun W, Jiang Y, Wang J, Yan J, Yang H, Wang X, Gao GF, Yang R, Wang J, Yu J. A glimpse of streptococcal toxic shock syndrome from comparative genomics of S. suis 2 Chinese isolates. PLoS ONE,2007,2:e315
71. Christensen P, Kronvall G. Capacity of group A, B, C, D, and G streptococci to agglutinate sensitized sheep red cells. Acta Pathologica et Microbiologica Scandinavica,1974,82:19-24
72. Clifton-Hadley F A. The epidemiology, diagnosis, treatment and control of Streptococcus suis type 2 infection. In:J.D. McKean (ed.). Proceedings of the American Association of Swine Practitioners, Minneapolis,1986,471-491
73. Clifton-Hadley F, Alexander T. Diagnosis of Streptococcus suis infection in pigs. In: E. Boden(ed.), Swine Practice,1991,115-126
74. Cock P J, Whitworth D E. Evolution of gene overlaps:relative reading frame bias in prokaryotic two-component system genes. J Mol Evol,2007a,64:457-462
75. Cock P J, Whitworth D E. Evolution of prokaryotic two-component system signaling pathways:gene fusions and fissions. Mol Biol Evol,2007b,24:2355-2357
76. Cotter P A, Jones A M. Phosphorelay control of virulence gene expression in Bordetella. Trends Microbiol,2003,11:367-373
77. Courtney H S, Li Y, Dale JB, Hasty D L. Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. Infect Immun, 1994,62:3937-3946
78. Daniely D, Portnoi M, Shagan M, Porgador A, Givon-Lavi N, Ling E, Dagan R & Nebenzahl Y M. Pneumococcal 6-phosphogluconate-dehydrogenase, a putative adhesin, induces protective immune response in mice. Clin Exp Immunol,2006, 144:254-263
79. del Campo Sepulveda E M, Altman E, Kobisch M, D'Allaire S, Gottschalk M. Detection of antibodies against Streptococcus suis capsular type 2 using a purified capsular polysaccharide antigen-based indirect ELISA. Vet Microbiol,1996,52:113-125 137.
80. de Greeff A, van Alphen L, Smith H E. Selection of Recombinant Antibodies Specific for Pathogenic Streptococcus suis by Subtractive Phage Display. Infect Immun,2000,68:3949-3955
81. de Greeff A, Buys H, Verhaar R, Dijkstra J, van Alphen L, Smith H E. Contribution of Fibronectin-Binding Protein to Pathogenesis of Streptococcus suis Serotype 2. Infect Immun,2002,70:1319-1325
82. Denholm I, Sawicki R M, Farnham A W. Factors affecting resistance to insecticides in houseflies, Musca domestica L. (Diptera:Muscidae). Ⅳ. The population biology of flies on animal farms in south-eastern England and its implications for the management of resistance. B Entomol Res,1985,75:143-158
83. Devriese L A, Sustronck B, Maenhouth T, Haesebrouck F. Streptococcus suis meningitis in a horse. Vet Rec,1990,127:68
84. Devriese L A, Haesebrouck F, de Herdt P, Dom P, Ducatelle R, Desmidt M, Messier S, Higgins R. Streptococcus suis infections in birds. Avian Pathol,1994,23:721-724
85. Dominguez-Punaro M C, Segura M, Plante M M, Lacouture S, Rivest S, Gottschalk M. Streptococcus suis serotype 2, an important swine and human pathogen, induces strong systemic and cerebral inflammatory responses in a mouse model of infection. J Immunol 2007,179:1842-1854
86. Elliott S D, Clifton-Hadley F, Tai J. Streptococcal infection in young pigs. V. An immunogenic polysaccharide from Streptococcus suis type 2 with particular reference to vaccination against streptococcal meningitis in pigs. J Hyg (Lond),1980, 85:275-285
87. Elliott S D, Tai J Y. The type specific polysaccharide of Streptococcus suis. J Exp Med,1978,148:1699-1704
88. Enright M R, Alexander T J L, Clifton-Hadley F A. Role of house￡ies (Musca domestica) in the epidemiology of Streptococcus suis type 2. Vet Rec,1987,121:132-133
89. Fabret C, Hoch J A. A two-component signal transduction system essential for growth of Bacillus subtilis:implications for anti-infective therapy. J Bacteriol,1998, 180:6375-6383
90. Fabret C, Feher V A, Hoch J A. Two-component signal transduction in Bacillus subtilis:how one organism sees its world. J Bacteriol,1999,181:1975-1983
91. Feng Y, Zheng F, Pan X, Sun W, Wang C, et al. Existence and characterization of allelic variants of Sao, a newly identified surface protein from Streptococcus suis. FEMS Microbiol Lett,2007,275:80-88
92. Federle M J, McIver K S, Scott J R. A response regulator that represses transcription of several virulence operons in the group A Streptococcus. J Bacteriol,1999, 181:3649-3657
93. Field H I, Buntan D, Done J T. Studies on piglet mortality. I. Streptococcal meningitis and arthritis. Vet Rec,1954,66:454-455
94. Forst S, Inouye M. Environmentally regulated gene expression for membrane proteins in Escherichia coli. Annu Rev Cell Biol,1988,4:21-42
95. Fukuchi K, Kasahara Y, Asai K, Kobayashi K, Moriya S, Ogasawara N. The essential two-component regulatory system encoded by yycF and yycG modulates expression of the ftsAZ operon in Bacillus subtilis. Microbiology,2000,146:1573-1583
96. Francois B, Gissot V, Ploy M C, Vignon P. Recurrent Due to Streptococcus suis. J Clin Microbiol,1998,36:2395
97. Frishman D, Mironov A, Mewes H W, Gelfand M. Combining diverse evidence for gene recognition in completely sequenced bacterial genomes. Nucleic Acids Res, 1998,26:2941-2947
98. Froeliger E H, Oetjen J, Bond J P, Fives-Taylor P. Streptococcus parasanguis pepO encodes an endopeptidase with structure and activity similar to those of enzymes that modulate peptide receptor signaling in eukaryotic cells. Infect Immun,1999, 67:5206-5214
99. Galina L, Vecht U, Wisselink H J, Pijoan C. Prevalence of various phenotypes of Streptococcus suis isolated from swine in the U.S.A. based on the presence of muraminidase-released protein and extracellular factor. Can J Vet Res,1996,60:72-74
100. Galcheva-Gargova Z, Derijard B, Wu I H, Davis R J. An osmosensing signal transduction pathway in mammalian cells. Science,1994,265:806-808
101. Giammarinaro P, Sicard M, Gasc A. Genetic and physiological studies of the CiaH-CiaR two-component signal-transducing system involved in cefotaxime resistance and competence of Streptococcus pneumoniae. Microbiol,1999,145:1859-1869
102. Gogolewski R P, Cook R W, O'Connell C J. Streptococcus suis serotypes associated with disease in weaned pigs. Aust Vet J,1990,67:202-204
103. Gottschalk M, Higgins R, Jacques M, Mittal K R, Henrichsen J. Description of 14 new capsular types of Streptococcus suis. J Clin Microbiol,1989,27:2633-2636
104. Gottschalk M, Higgins R, Jacques M, Beaudoin M, Henrichsen J. Isolation and characterization of Streptococcus suis capsular types 9-22. J Vet Diagn Invest,1991a, 3:60-65
105. Gottschalk M, S egura M. The pathogenesis of the meningitis caused by Streptococcus suis:the unresolved questions. Vet Microbiol,2000,76:259-272
106. Gottschalk M, Higgins R, Jacques M, Beaudoin M, Henrichsen J. Characterization of six new capsular types (23 through 28) of Streptococcus suis. J Clin Microbiol, 1991b,29:2590-2594
107. Granlund M, Oberg L, Scum M, Norgren M. Identification of a novel insertion element, IS 1548, in group B streptococci, predominantly in strains causing endocarditis. J Infect Dis,1998,177:967-976
108. Graham M R, Smoot L M, Migliaccio C A, Virtaneva K, Sturdevant D E, Porcella S F, Federle M J, Adams G J, Scott J R, Musser J M. Virulence control in group A Streptococcus by a two-component gene regulatory system:global expression profiling and in vivo infection modeling. P Natl Acad Sci USA,2002,99:13855-13860
109. Graveline R, Segura M, Radzioch D, Gottschalk M. TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. Int Immunol,2007,19:375-389
110. Guise H J, Penny R H C, Duthie A N S. Streptococcal meningitis in pigs. Vet Rec, 1985,117:43-44
111. Guenzi E, Gasc A M, Sicard M A, Hakenbeck R. A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae. Mol Microbiol,1994,12:505-515
112. Goulielmos G N, Eliopoulos E, Loukas M, Tsakas S. Functional constraints of 6-phosphogluconate dehydrogenase(6-PGD) based on sequence and structural information. J Mol Evol,2004,59:358-371
113. Gunther B, Ozegowski J H, Kohler W. Occurrence of extracellular hyaluronic acid and hyaluronate lyase in streptococci of groups A, B, C, and G. Zentralbl Bakteriol, 1996,285:64-73
114. Heidt M C, Mohamed W, Hain T, Vogt P R, Chakraborty T, Domann E. Human Infective Endocarditis Caused by Streptococcus suis Serotype 2. J Clin Microbiol, 2005,43:4898-4901
115. Heath A, DiRita V J, Barg N L, Engleberg N C. A twocomponent regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infect Immun, 1999,67:5298-5305
116. Higgins R, Gottschalk M. Distribution of Streptococcus suis capsular types in 1994. Can Vet J,1995,36:320
117. Higgins R, Gottschalk M. Quebec. Distribution of Streptococcus suis capsular types in Canada in 1991, Can Vet J,1992,33:406
118. Hoie S, Falk K, Lium B M. An abattoir survey of pneumonia and pleuritis in slaughter weight swine from 9 selected herds. Ⅳ. Bacteriological findings in chronic pneumonic lesions. Acta Vete Scand,1991,32:395-402
119. Holden M T G, Hauser H, Sanders M,Ngo T H, Cherevach I, Cronin A, Goodhead I, Mungall Ka, Quail M A, Price C, Rabbinowitsch E, Sharp S, Croucher N J, Chieu T B, Mai NTH, Diep T S, Chinh N T, Kehoe M, Leigh J A, Ward P N, Dowson C G, Whatmore A M, Chanter N, Iversen P, Gottschalk M, Slater J D, Smith H E, Spratt B G,Xu J, Ye C, Bentley S, Barrell BG, Schultsz C, Maskell D J, Parkhill J. Rapid Evolution of Virulence and Drug Resistance in the Emerging Zoonotic Pathogen Streptococcus suis. PLoS ONE,2009,4:e6072
120. Holt M E, Enright M R, Alexander T J. Immunisation of pigs with live cultures of Streptococcus suis type 2. Rev Vet Sci,1988,45:349-352
121. Holt M E, Enright M R, Alexander T J. Immunisation of pigs with killed cultures of Streptococcus suis type 2. Rev Vet Sci,1990,48:23-27
122. Homer K, Shain H, Beighton D. The role of hyaluronidase in growth of Streptococcus intermedius on hyaluronate. Adv Exp Med Biol,1997,418:681-683
123. Homer K A, Denbow L, Whiley R A, Beighton D. Chondroitin sulfate depolymerase and hyaluronidase activities of viridans streptococci determined by a sensitive spectrophotometric assay. J Clin Microbiol,1993,31:1648-1651
124. Hommez J, Castryck L A, Henrichsen J. Prevalence of Streptococcus suis and methods of identification. In:M. Pensaert, J. Hoorens, P. Lampo, P. Bonte,W. Coussement and P. Debouck (eds). Proceedings of the International Pig Veterinary Society Congress, Gent,1984,8:134
125. Hommez J, Willepit J, Cassimon 0, Castryck F, Ceyssens K, Devriese L A. Streptococcus suis and other streptococcal species as a cause of extramammary infection in ruminants. Vet Rec,1988,123:626-627
126. Huang YT, Teng LJ, Ho SW, Hsueh PR. Streptococcus suis infection. J Microbiol Immunol Infect,2005,58:306-313
127. Hynes W L, Walton S L. Hyaluronidases of Gram-positive bacteria. FEMS Microbiol Lett,2000,183:201-207
128. Iglarz M, Schiffrin E L. Role of endothelin-1 in hypertension. Curr Hypertens Rep, 2003,5:144
129. Jacobs A A C, Loeffen P L W, van den Berg A J G, Storm P K. Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. Infect Immun,1994,62:1742-1748
130. Jacobs A A C, van den Berg A J G, Loeffen P L W. Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis. Vet Rec,1996,139:225-228
131. Jensen J, van Dorssen C A. Meningo-encephalitis bij vafkens door streptococcen. Tijdschr Diergeneesk,1951,76:815-832
132. Jiang S M, Cieslewicz M J, Kasper D L, Wessels M R. Regulation of virulence by a two-component system in group B streptococcus. J Bacteriol,2005,187:1105-1113
133. Joh D, Wann E R W, Kreikemeyer B, Speziale P, Hook M. Role of fibronectin-binding MSCRAMMS in bacterial adherence and entry into mammalian cells. Matrix Biol,1999,18:211-223
134. Kataoka Y, Sugimoto C, Nakazawa M, Morozuni T, Kashiwazaki M. The epidemiological studies of Streptococcus suis infections in Japan from 1987 to 1991. J Vet Med Sci,1993,55:623-626
135. Kay R, Cheng A F, Tse C Y. Streptococcus suis infection in Hong Kong. Quarterly J Med,1995,88:39-47
136. King S J, Heath P J, Luque I, Tarradas C, Dowson C G, Whatmore A M. Distribution and Genetic Diversity of Suilysin in Streptococcus suis Isolated from Different Diseases of Pigs and Characterization of the Genetic Basis of Suilysin Absence. Infect Immun,2001,69:7572-7582
137. Koehne G, Maddux F L, Cornell W D. Lancefield group R streptococci associated with pneumonia in swine. Am J Vet Res,1979,40:1640-1641
138. Korth P, Bohle R M, Corvol P, Pinet F. Cellular distribution of endothelin converting enzyme-1 in human tissues. J Histochem Cytochem,1999,47:447
139. Kox L F F, Wosten M M S M, Groisman E A. A small protein that mediates the activation of a two-component system by another two-component system. EMBO J, 2000,19:1861-1872
140. Kuchma S L, Connolly J P, O'Toole G A. A three-component regulatory system regulates biofilm maturation and type III secretion in Pseudomonas aeruginosa. J Bacteriol,2005,187:1441-1454
141. Lalonde M, Segura M, Lacouture S, Gottschalk M. Interactions between Streptococcus suis serotype 2 and different epithelial cell lines. Microbiol,2000, 146:1913-1921
142. Lanie J A, Ng W L, Kazmierczak K M, Andrzejewski T M, Davidsen T M, Wayne K J, Tettelin H, Glass J I, Winkler M E. Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J Bacteriol,2007,189:38-51
143. Lamy M C, Zouine M, Fert J, Vergassola M, Couve E, Pellegrini E, Glaser P, Kunst F, Msadek T, Trieu-Cuot P, Poyart C.CovS/CovR of group B streptococcus:a two-component global regulatory system involved in virulence. Mol Microbiol,2004, 54:1250-1268
144. Li Y H, Lau P C, Tang N, Svensater G, Ellen R P, Cvitkovitch D G Novel two-component regulatory system involved in biofilm formation and acid resistance in Streptococcus mutans. J Bacteriol,2002,184:6333-6342
145. Li M, Wang C, Feng Y, Pan X, Cheng G, Wang J, Ge J, Zheng F, Cao M, Dong Y, Liu D, Wang J, Lin Y, Du H, Gao GF, Wang X, Hu F, Tang J. SalK/SalR, a two component signal transduction system, is essential for full virulence of highly invasive Streptococcus suis serotype 2. PLoS ONE,2008,3:e2080
146. Ling E W Y, Noya F J D, Ricard G, Beharry K, Mills E L, Aranda J V. Biochemical mediators of meningeal inflammatory response to group B Streptococcus in the newborn piglet model. Pediatr Res,1995,38:981-987
147. Liang X, Zheng L, Landwehr C, Lunsford D, Holmes D, Ji Y. Global regulation of gene expression by ArlRS, a two-component signal transduction regulatory system of Staphylococcus aureus. J Bacteriol,2005,187:5486-5492
148. Lyon G J, Mayville P, Muir T W, Novick R P. Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. P Natl Acad Sci USA, 2000,97:13330-13335
149. Lunsford R D, London J. Natural genetic transformation in Streptococcus gordonii: comX imparts spontaneous competence on strain wicky. J Bacteriol,1996, 178:5831-5835
150. Lun S, Perez-Casal J, Connor W, Willson P J. Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2. Microb Pathog.2003,34:27-37
151. Maeda T, Wurgler-Murphy S M, Saito H. A two-component system that regulates an osmosensing MAP kinase cascade in yeast. Nature,1994,369:242-245
152. Maeda T, Takekawa M, Saito H. Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor. Science,1995,269:554-558
153. Martin P K, Li T, Sun D, Biek D P, Schmid M B. Role in cell permeability of an essential two-component system in Staphylococcus aureus. J Bacteriol,1999, 181:3666-3673
154. Marcelo G, Mariela S. The pathogenesis of the meningitis caused by Streptococcus suis:the unresolved questions. Vet Microbiol,2000,76:259-272
155. Mascher T, Heintz M, Zahner D, Merai M, Hakenbeck R. The CiaRH system of Streptococcus pneumoniae prevents lysis during stress induced by treatment with cell wall inhibitors and mutations in pbp2x involved in beta-lactam resistance. J Bacteriol,2006,188:1959-1968
156. McKessar S J, Hakenbeck R. The Two-Component Regulatory System TCS08 Is Involved in Cellobiose Metabolism of Streptococcus pneumoniae R6. J Bacteriol, 2007,189:1342-1350
157. Mascher T, Merai M, Balmelle N, de Saizieu A, Hakenbeck R. The Streptococcus pneumoniae. cia regulon:CiaR target sites and transcription profile analysis. J Bacteriol,2003,185:60-70
158. Mierau I, Tan P S, Haandrikman A J, Mayo B, Kok J, Leenhouts K J, Konings W N, Venema G. Cloning and sequencing of the gene for a lactococcal endopeptidase, an enzyme with sequence similarity to mammalian enkephalinase. J Bacteriol,1993, 175:2087-2096
159. Miller A A, Engleberg N C, DiRita V J. Repression of virulence genes by phosphorylation-dependent oligomerization of CsrR at target promoters in S.pyogenes. Mol Microbiol,2001,40:976-990
160. McCluskey J, Hinds J, Husain S, Witney A, Mitchell T J. A two-component system that controls the expression of pneumococcal surface antigen A (PsaA) and regulates virulence and resistance to oxidative stress in Streptococcus pneumoniae. Mol Microbiol,2004,51:1661-1675
161. Mizuno T, Mizushima S. Signal transduction and gene regulation through the phosphorylation of two regulatory components:the molecular basis for the osmotic regulation of the porin genes. Mol Microbiol,1990,4:1077-1082
162. Moss J E, Fisher P E, Vick B, Groisman E A, Zychlinsky A. The regulatory protein PhoP controls susceptibility to the host inflammatory response in Shigella flexneri. Cell Microbiol,2000,2:443-52
163. Mouslim C, Delgado M, Groisman E A. Activation of the RcsC/YojN/RcsB phosphorelay system attenuates Salmonella virulence. Mol Microbiol,2004,54:386-395
164. Mwaniki C G, Robertson I D, Trott D J, Atyeo R F, Lee B J, Hampson D J. Clonal analysis and virulence of Australian isolates of Streptococcus suis type 2. Epidemiol Infect,1994,113:321-334
165. Navarre W W, Halsey T A, Walthers D, Frye J, McClelland M, Potter J L, Kenney L J, Gunn J S, Fang F C, Libby S J. Co-regulation of Salmonella enterica genes required for virulence and resistance to antimicrobial peptides by SlyA and PhoP/PhoQ. Mol Microbiol,2005,56:492-508
166. Naidoo V, Naidoo S, Mahabeer R, Raidoo D M. Cellular distribution of the endothelin system in the human brain. J Chem Neuroanat,2004,27:87
167. Ng W L, Tsui H C, Winkler M E. Regulation of the pspA virulence factor and essential pcsB murein biosynthetic genes by the phosphorylated VicR (YycF) response regulator in Streptococcus pneumoniae. J Bacteriol,2005,187:7444-7459
168. Novick R P. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol,2003,48:1429-1449
169. Norton P M, Rolph C, Ward P N, Bentley R W, Leigh J A. Epithelial invasion and cell lysis by virulent strains of Streptococcus suis is enhanced by the presence of suilysin. FEMS Immunol Med Microbiol,1999,26:25-35
170. Oetjen J, Fives-Taylor P, Froeliger E. Characterization of a streptococcal endopeptidase with homology to human endothelin-converting enzyme. Infect Immun,2001,69:58-64
171. Osaki M, Takamatsu D, Shimoji Y, Sekizaki T. Characterization of Streptococcus suis Genes Encoding Proteins Homologous to Sortase of Gram-Positive Bacteria. J Bacteriol,2002,184:971-982
172. Osaki M, Takamatsu D, Shimoji Y, Sekizaki T. Allelic variation in srtAs of Streptococcus suis strains. FEMS Microbiol Lett,2003,219:195-201
173. Ossowicz C J, Pointon A M, Davies P R. Streptococcus suis isolated from pigs in South Australia. Aust Vet J,1989,66:377-378
174. Ota I M, Varshavsky A. A yeast protein similar to bacterial two-component regulators. Science,1993,262:566-569
175. Pan X, Ge J, Li M, Wu B, Wang C, Wang J, Feng Y, Yin Z, Zheng F, Cheng G, Sun W, Ji H, Hu D, Shi P, Feng X, Hao X, Dong R, Hu F, Tang J. The Orphan Response Regulator CovR:a Globally Negative Modulator of Virulence in Streptococcus suis Serotype 2. J Bacteriol,2009,191:2601-2612
176. Parkinson J S, Kofoid E C. Communication modules in bacterial signaling proteins. Annu Rev Genet,1992,26:71-112
177. Pearson W R, Lipman D J. Improved Tools for Biological Sequence Comparison. P Natl Acad Sci USA.1988,85:2444-2448
178. Pedroli S, Kobisch M, Beauchet O, Chaussinand J P, Lucht F. Streptococcus suis bacteremia. Presse Med,2003,32:599-601
179. Perch B, Kristjansen P, Skadhauge K. Group R Streptococci pathogenic for man: two cases of meningitis and one fatal case of sepsis. Acta Pathol Microbiol Scand, 1968,74:69-76
180. Perch B, Pedersen K B, Henrichsen J. Serology of capsulated streptococci pathogenic for pigs:six new serotypes of Streptococcus suis. J Clin Microbiol,1983, 17:993-996
181. Pestova E V, Havarstein L S, Morrison D A. Regulation of competence for genetic transformation in Streptococcus pneumoniae by an auto-induced peptide pheromone and a two-component regulatory system. Mol Microbiol,1996,21:853-862
182. Pritchard D G, Lin B, Willingham T R, Baker J R. Characterization of the group B streptococcal hyaluronate lyase. Arch Biochem Biophys,1994,315:431-437
183. Posas F, Wurgler-Murphy S M, Maeda T, Witten E A, Thai T C, Saito H. Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the SLN1-YPD1-SSK1 "two-component" osmosensor. Cell,1996,86:865-875
184. Postma P W, Lengeler J W, Jacobson G R. Phosphoenolpyruvate:carbohydrate phosphotransferase systems of bacteria. Microbiol Rev,1993,57:543-594
185. Power S B. Streptococcus suis type 2 infection in pigs. Vet Rec,1978,102:215-216
186. Prieto C, Pena J, Suarez P, Imaz M, Castro J M. Isolation and distribution of Streptococcus suis capsular types from diseased pigs in Spain. Zentralblatt fur Veterinarmedizin, Reihe B,1993,40:544-548
187. Quessy S, Busque P, Higgins R, Jacques M, Dubreuil J D. Description of an albumin binding activity for Streptococcus suis serotype 2. FEMS Microbiol Lett, 1997,147:245-250
188. Quessy S, Dubreuil D, Higgins R. Immunization of mice against Streptococcus suis type 2 infection using a live avirulent strain. Can J Vet Res,1994,58:299-301
189. Rawlings N D, Barrett A J. Evolutionary families of metallopeptidases. Methods Enzymol,1995,248:183-228
190. Reams R Y, Harrington D D, Glickman L T, Thacker H L, Bowersock T L. Fibrinohemorrhagic pneumonia in pigs naturally infected with Streptococcus suis. J Vet Diagn Invest,1995,7:406-408
191. Robertson I D, Blackmore D K. Prevalence of Streptococcus suis types 1 and 2 in domestic pigs in Australia and New Zealand. Vet Rec,1989,124:391-394
192. Robertson I D, Blackmore D K. Experimental studies on the comparative infectivity and pathogenicity of Streptococcus suis type 2. Ⅱ. Porcine and human isolates in laboratory animals. Epidemiol Infect,1990,105:479-484
193. Rolland K, Marois C, Siquier V, Cattier B, Quentin R. Genetic features of Streptococcus agalactiae strains causing severe neonatal infections, as revealed by pulsed-field gel electrophoresis and hylB gene analysis. J Clin Microbiol,1999, 37:1892-1898
194. Rosenkranz M, Elsner H A, Sturenburg H J, Weiller C, Rother J, Sobottka I. Streptococcus suis meningitis and septicemia contracted from a wild boar in Germany. J Neurol,2003,250:869-870
195. Sanford S E. Gross and histopathological findings in unusual lesions caused by Streptococcus suis in pigs.Ⅱ. Central nervous system lesions. Can J Vet Res,1987, 51:486-489
196. Sanford S E. Streptococcus suis:a strategic update. In:Proceedings of the Annual Meeting of the American Association of Swine Practitioners, Des Moines,1989, 193-195
197. Sanford S E, Tilker M E. Streptococcus suis type Ⅱ-associated diseases in swine: observations of a one-year study. J Am Vet Med Asso,1982,181:673-676
198. Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A, Tuomanen E. The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J Exp Med,1990,171:439-448
199. Schaufuss P, Sting R, Schaeg W, Blobel H. Isolation and characterization of hyaluronidase from Streptococcus uberis. Zentralbl Bakteriol,1989,271:46-53
200. Seddon S V, Hemingway I, Borriello S P. Hydrolytic enzyme production by Clostridium difficile and its relationship to toxin production and virulence in the hamster model. J Med Microbiol,1990,31:169-74
201. Segers R P, Kenter T, de Haan L A, Jacobs A A. Characterisation of the gene encoding suilysin from Streptococcus suis and expression in field strains. FEMS Microbiol Lett,1998,167:255-261
202. Segura M, Cleroux P, Gottschalk M. Streptococcus suis and group B Streptococcus differ in their interactions with murine macrophages. FEMS Immunol Med Microbiol,1998,21:189-195
203. Segura M, Gottschalk M. Extracellular virulence factors of streptococci associated with animal diseases. Front Biosci,2004,9:1157-1188
204. Segura M, Gottschalk M. Streptococcus suis interactions with the murine macrophage cell line J774:adhesion and cytotoxicity. Infect Immun,2002,70:4312-4322
205. Segura M, Stankova J, Gottschalk M. Heat-Killed Streptococcus suis Capsular Type 2 Strains Stimulate Tumor Necrosis Factor Alpha and Interleukin-6 Production by Murine Macrophages. Infect Immun,1999,67:4646-4654
206. Serhir B, Dubreuil D, Higgins R, Jacques M. Purification and characterization of a 52-kilodalton immunoglobulin G-binding protein from Streptococcus suis capsular type 2. J Bacteriol,1995,177:3830-3836
207. Serhir B, Higgins R, Foiry B, Jacques M. Detection of immunoglobulin-binding proteins in Streptococcus suis. J Gen Microbiol,1993,139:2953-2958
208. Sessa W C, Kaw S, Hecker M, Vane J R.The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Bioph Res Co,1991,174:613
209. Sihvonen L, Kurl D N, Henrichsen J. Streptococcus suis isolated from pigs in Finland. Acta Vet Scand,1988,29:9-13
210. Smith H E, Buijs H, de Vries R R, Wisselink H J, Stockhofe-Zurwieden N, Smits M A. Environmentally regulated genes of Streptococcus suis:identification by the use of iron-restricted conditions in vitro and by experimental infection of piglets. Microbiology,2001,147:271-280
211. Smith H E, Damman M, van der Velde J, Wagenaar F, Wisselind H J, Stockhofe-zurwieden N, Smits M A. Identification and Characterization of the cps Locus of Streptococcus suis Serotype 2:the Capsule Protects against Phagocytosis and Is an Important Virulence Factor. Infect Immun,1999,67:1750-1756
212. Smith H E, de Vries R, van't Slot R, Smits M A. The cps locus of Streptococcus suis serotype 2:genetic determinant for the synthesis of sialic acid. Microb Pathog, 2000,29:127-134
213. Smith H E, Vecht U, Wisselink H J, Stockhofe-Zurwieden N, Biermann Y, Smits M A. Mutants of Streptococcus suis types 1 and 2 impaired in expression of muramidase-released protein and extracellular protein induce disease in newborn germfree pigs. Infect Immun,1996,64:4409-4412
214. Smith H E, Vecht U, Gielkens A L, Smits M A. Cloning and nucleotide sequence of the gene encoding the 136-kilodalton surface protein (muramidase-released protein) of Streptococcus suis type 2. Infect Immun,1992,60:2361-2367
215. Smolen P, Baxter D A, Byrne J H. Modeling transcriptional control in gene networks-methods, recent results, and future directions. Bull Math Biol,2000, 62:247-292
216. Sorensen N S, Tegtmeier C, Andresen L O, Pineiro M, Toussaint M J M, Campbell F M, Lampreave F, Heegaard P M H. The porcine acute phase protein response to acute clinical and subclinical experimental infection with Streptococcus suis. Vet Immunol Immunopathol,2006,113:157-168
217. Sprenger H, Rosler A, Tonn P, Braune H J, Huffmann G, Gemsa D. Chemokines in the cerebrospinal fluid of patients with meningitis. Clin Immunol Immunopathol, 1996,80:155-161
218. Staats J J, Feder I, Okwumabua O, Chengappa M M. STREPTOCOCCUS SUIS: PAST AND PRESENT. Vet Res Commun,1997,21:381-407.
219. Staats J J, Plattner B L, Stewart G C, Changappa M M. Presence of the Streptococcus suis suilysin gene and expression of MRP and EF correlates with high virulence in Streptococcus suis type 2 isolates. Vet Microbiol,1999,70:201-211
220. Staats J J, Plattner B L, Nietfeld J, Dritz S, Chengappa M M. Use of ribotyping and hemolysin activity to identify highly virulent Streptococcus suis type 2 isolates. J Clin Microbiol,1998,36:15-19
221. Stephenson K, Yamaguchi Y, Hoch JA. The mechanism of action of inhibitors of bacterial two-component signal transduction systems. J Biol Chem,2000, 275:38900-38904
222. Stock J B, Ninfa A J, Stock A M. Protein phosphorylation and regulation of adaptive responses in bacteria. Microbiol Rev,1989,53:450-490
223. Stock J B, Stock A M, Mottonen J M. Signal transduction in bacteria. Nature,1990, 344:395-400
224. Strangmann E, Froleke H, Kohse K P. Septic shock caused by Streptococcus suis: Case report and investigation of a risk group. Int J Hyg Environ Health,2002, 205:385-392
225. Takamatsu D, Osaki M, Sekizaki T. Construction and characterization of Streptococcus suis-Escherichia coli shuttle cloning vectors. Plasmid,2001,45:101-113
226. Takamatsu D, Osaki M, Sekizaki T. Evidence for Lateral Transfer of the Suilysin Gene Region of Streptococcus suis. J Bacterial,2002,184:2050-2057
227. Takamatsu D, Osaki M, Tharaviehitkul P, Takai S, Sekizaki T. Allelic variation and prevalence of serum opacity factor among the Streptococcus suis population. J Med Microbiol,2008,57:488-494
228. Tang J, Wang C, Feng Y, Yang W, Song H, Chen Z, Yu H, Pan X, Zhou X, Wang H, Wu B,Wang H, Zhao H, Lin Y, Yue J, Wu Z, He X, Gao F, Khan A H, Wang J, Zhao G, Wang Y, Wang X, Chen Z, Gao GF. Streptococcal toxic shock syndrome caused by Streptococcus suis serotype 2. PLoS Med,2006,3:e151
229. Tarradas C, Arenas A, Maldonado A, Luque I, Miranda A, Perea A. Identfication of Streptococcus suis isolated from swine:proposal for biochemical parameters. J Clin Microbiol,1994,32:578-580
230. Tarradas C, Borge C, Arenas A, Maldonado A, Astorga R, Miranda A, Luque I. Suilysin production by Streptococcus suis isolated from diseased and healthy carrier pigs in Spain. Vet Rec,2001a,148:183-184
231. Tarradas C, Luque I, de Andres D, Abdel-Aziz Shahein Y, Pons P, Gonzalez F, Borge C, Perea A. Epidemiological relationship of human and swine Streptococcus suis isolates. J Vet Med B Infect Dis Vet Public Health,2001b,48:347-355
232. Throup J P, Koretke K K, Bryant A P, Ingraham K A, Chalker A F, Ge Y, Marra A, Wallis N G, Brown J R, Holmes D J, Rosenberg M, Burnham M K. A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol Microbiol,2000,35:566-576
233. Townsend GC, Scheld WM. Microbe-endothelium interactions in blood-brain barrier permeability during bacterial meningitis. ASM News,1995,61:294-298
234. Trottier S, Higgins R, Brochu G, Gottschalk M. A case of human endocarditis due to Streptococcus suis in North America. Rev Infect Dis,1991,13:1251-1252
235. Tuomanen E. Entry of pathogens into the central nervous system. FEMS Microbiol Rev,1996,18:289-299
236. Ulijasz A T, Andes D R, Glasner D R, Weisblum B. Regulation of iron transport in Streptococcus pneumoniae by RitR, an orphan response regulator. J Bacteriol,2004, 186:8123-8136
237. Vadeboncoeur N, Segura M, Al-Numani D, Vanier G, Gottschalk M. Proinflammatory cytokine and chemokine release by human brain micro vascular endothelial cells stimulated by Streptococcus suis serotype 2.FEMS Immun Med Microbiol,2003,35:49-58
238. Vanier G, Segura M, Fried P, Lacouture S, Gottschalk M. Invasion of Porcine Brain Microvascular Endothelial Cells by Streptococcus suis Serotype 2. Infect Immun, 2004,72:1441-1449
239. Vanier G, Sekizaki T, Dominguez-Punaro M C, Esgleas M, Osaki M, Takamatsu D, Segura M, Gottschalk M. Disruption of srtA gene in Streptococcuc suis results in decreased interactions with endothelial cells and extracellular matrix proteins. Vet Microbiol,2008,127:417-424
240. Varughese K I. Molecular recognition of bacterial phosphorelay proteins. Curr Opin Microbiol,2002,5:142-148
241. Vatter H, Mursch K, Zimmermann M, Zilliken P, Kolenda H, Seifert V, Schilling L. Endothelin-converting enzyme activity in human cerebral circulation. Neurosurgery, 2002,51:445
242. Vela A I, Goyache J, Tarradas C, Luque I, Mateos A, Moreno M A, Borge C, Perea J A, Dominguez L, Fernandez-Garayzabal J F. Analysis of genetic diversity of Streptococcus suis clinical isolates from pigs in Spain by pulsed-field gel electrophoresis. J Clin Microbiol,2003,41:2498-2502
243. Vecht U, Wisselink H J, Jellema M L, Smith H E. Identification of two proteins associated with virulence of Streptococcus suis type 2. Infect Immun,1991,59:3156-3162
244. Vecht U, Wisselink H J, van Dijk J E, Smith H E. Virulence of Streptococcus suis type 2 strains in newborn germfree pigs depend on phenotype. Infect Immun,1992, 60:550-556
245. Vecht U, Arends J P, van der Molen E J, van Leengoed L A M G.. Differences in virulence between two strains of Streptococcus suis type 2 after experimentally induced infection of newborn germfree pigs. Am J Vet Res,1989,50:1037-1043
246. Verhoef J, Mattsson E. The role of cytokines in gram-positive bacterial shock. Trends Microbiol,1995,3:136-140
247. Wang C, Li M, Feng Y, Zheng F, Fong Y, Pan, X, Cheng G, Dong R, Hu D, Feng X, Ge J, Liu D, Wang J, Gao M, Hu F, Tang J. The involvement of sortase A in high virulence of STSS-causing Streptococcus suis serotype 2. Arch Micorbiol,2009, 191:23-33
248. West A H, Stock A M. Histidine kinases and response regulator proteins in two-component signaling systems. Trends Biochem Sci,2001,26:369-376
249. Williams A E, Blakemore W F, Alexander T J L. A murine model of Streptococcus suis type 2 meningitis in pigs. Res Vet Sci,1988,45:394-399
250. Wilson S M, Norton P, Haverson K, Leigh J, Bailey M. Interactions between Streptococcus suis serotype 2 and cells of the myeloid lineage in the palatine tonsil of the pig. Vet Immunol Immunop.2007,117:116-23
251. Windsor R S, Elliott S D. Streptococcal infection in young pigs. Ⅳ. An outbreak of streptococcal meningitis in weaned pigs. Journal of Hygiene,1975,75:69-78
252. Windsor R S. Meningitis in pigs caused by Streptococcus suis type 2. Vet Rec,1977, 101:378-379
253. Wisselink H J, Smith H E, Stockhofe-Zurwieden N, Peperkamp K, Vecht U. Distribution of capsular types and production of muramidase-released protein (MRP) and extracellular factor (EF) of Streptococcus suis strains isolated from diseased pigs in seven European countries. Vet Microbiol,2000,74:237-248
254. Wisselink H J, Vecht U, Stockhofe-Zurwieden N, Smith H E. Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine. Vet Rec,2001, 148:473-477
255. Wisselink H J, Stockhofe-Zurwieden N, Hilgers L, Smith H E. Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of Streptococcus suis type 2. Vet Microbiol,2002,84:155-168
256. Wurgler-Murphy S M, Saito H. Two-component signal transducers and MAPK cascades. Trends Biochem Sci,1997,22:172-176
257. Wu T, Chang H, Tan C, Bei W, Chen H. The orphan response regulator RevSC21 controls the attachment of Streptococcus suis serotype-2 to human laryngeal epithelial cells and the expression of virulence genes. FEMS Microbiol Lett,2009, 292:170-181
258. Yang W Z, Yu H J, Jing H Q, Xu J G, Chen Z H, Zhu X P, Wang H, Liu X C, Wang S W, Liu L G, Zu R Q, Luo L Z, Xiang N J, Liu H L, Zhong W J, Liu L, Meng L, Yuan H, Gao Y J, Du H M, Ou Y B, Ye C Y, Jin D, Lv Q, Cui Z G, Huang Y, Zhang S Y, An X D, Huang T, Zhou X Y, Feng L, Pang Q D, Shu Y L, Wang Y. An outbreak of human Streptococcus suis serotype 2 infection presenting with toxic shock syndrome in Sichuan, China. Zhonghua Liu Xing Bing Xue Za Zhi,2006,27:185-191
259. Yarwood J M, McCormick J K, Schlievert P M. Identification of a novel two-component regulatory system that acts in global regulation of virulence factors of Staphylococcus aureus. J Bacteriol,2001,183:1113-1123
260. Yu H, Jing H, Chen Z, Zheng H, Zhu X, Wang H, Wang S, Liu L, Zu R, Luo L, Xiang N, Liu H, Liu X, Shu Y, Lee S, Chuang S, Wang Y, Xu J, Yang W, China SSG. Human Streptococcus suis outbreak, Sichuan, China. Emerg Infect Dis,2006, 12:914-920
261. Zahner D, Kaminski K, van der Linden M, Mascher T, Merai M, Hakenbeck R. The ciaR/ciaH regulatory network of Streptococcus pneumoniae. J Mol Microbiol Biotechnol,2002,4:211-216
262. Zhu H, He J, Jing H B, Wang Z Q, Duan Q. Isolation and identification of Streptococcus suis serotype 2 from sick-pig samples of Sichuan province. Wei Sheng Wu Xue Bao,2006,46:635-638
2.程功,李明,郑峰,王晶,王长军,潘秀珍,范红结,唐家琪.Ⅱ型猪链球菌二元信号转导系统2148hk/rr基因敲除突变体的构建.微生物学通报,2008,35：25-29
3.狄晴,许利刚,张颖冬,曹辉.内皮素转换酶基因在急性脑梗死患者外周血中的表达及临床其意义.临床神经病学杂志,2007,20：92-94
4.董国英,李敏,向华.人畜共患新病原——猪链球菌2型的研究进展.广东畜牧兽医科技,2005,30：8-13
5.何孔旺,倪艳秀,王继春.猪链球菌2型的分子流行病学研究.中国人兽共患病杂志,2002,18：45-47
6.姜成刚,刘荻萩,蔡雪辉.猪链球菌2型对PK-15细胞的黏附动力学.中国畜牧兽医,2008,35：27-29
7.金冬雁,黎孟枫等译.J.萨姆布鲁克,EF弗里奇,T曼尼阿蒂斯著.分子克隆实验指南,第二版.科学出版社,1989.
8.李立虎.猪链球菌病的研究进展.畜牧与饲料科学,2009,30：173-174
9.李明,胡福泉,唐家琪.二元信号转导系统与细菌的致病性.微生物学杂志,2007,27：50-54
10.马有智,方维焕.猪链球菌血清2型JX02株溶血素基因的克隆及序列分析.中国兽医杂志,2003,23：460-462
11.莫才清,李阜棣,周俊初.原核生物细胞如何对环境因子作出响应、其信号传导路径及对逆境(非生物物质降解)的适应性.微生物学杂志,1997,17：41-46
12.邱全胜.双组分系统——细胞识别渗透胁迫信号的感应器.生物化学与生物物理进展,2000,27：593-596
13.沈艳,崔立,华修国.猪链球菌2型引起脑膜炎致病机制的研究进展.中国畜牧兽医,2007,34：92-94
14.孙理云,范红结,陆承平.猪链球菌2型FBPS的纤连蛋白结合部位的初步确定.微生物学报,2005,45：753-756
15.孙理云.猪链球菌2型与宿主细胞的相互作.中国人兽共患病学报,2008,24：775-776
16.唐家琪,朱进,郭恒彬,胡晓抒,朱凤才,刘光中.猪链球菌引起人中毒性休克综合征和脑膜脑炎的流行病学调查及病原学研究.第三军医大学学报,2001,23：1292-1295
17.魏武,丁国徽,王晓婧,孙景春,屠康,郝沛,王川,曹志伟,石铁流,李亦学.猪链球菌全基因组序列比较分析.科学通报,2006,51：808-818
18.吴德,罗会明,郑慧贞.人—猪链球菌病流行病学研究进展.中华流行病学杂志,2007,28：402-404
19.吴涛.猪链球菌2型revS基因缺失突变株的构建及其生物学特性研究和HYL蛋白与宿主蛋白质相互作用的研究.[博士学位论文].武汉：华中农业大学图书馆,2008
20.徐敏,蔡雪辉,王淑杰,刘永刚.猪链球菌2型毒力因子研究进展.动物医学进展,2009,30：65-70
21.杨俊兴.猪链球菌2型抗体检测试纸条的制备及FBPS与宿主蛋白质相互作用研究.[博士学位论文].武汉：华中农业大学图书馆,2007
22.杨维中,刘伦光,高永军,安向东,余宏杰,景怀琦,徐建国,陈志海,祝小平,汪华,刘学成,王世文,祖荣强,罗隆泽,向妮娟,刘红露,钟文君,刘莉,孟玲,袁珩,杜化茂等.四川省一起伴中毒性休克综合征的人感染猪链球菌2型暴发.中华流行病学杂志,2006,27：185-191
23.曾巧英,陆承平.猪链球菌2型对扁桃腺上皮细胞的黏附和侵袭作用.微生物学报,2004,44：523-525
24.曾巧英,陆承平.猪链球菌2型溶菌酶释放蛋白诱导上皮细胞融合和凋亡.微生物学报,2003,43：407-412
25.曾小涛,袁媛,郑玉玲,周冬生,姜永强,陈福生.猪链球菌2型全基因DNA芯片的研制及基因表达谱技术平台的建立.生物技术通讯,2009,658-661
26.查红波.2型猪链球菌病研究进展.江西饲料,2005,26：27-29
27.张安定,金梅林,陈焕春.猪链球菌2型研究进展(综述).养殖与饲料,2005,10：13-18
28.张淑伟,鲁成武.猪链球菌2型的致病机制.生命的化学,2006,26：178-180
29.郑继平,郭桂英,韦双双,周海龙,张兆山.猪链球菌2型疫苗研究进展.生物技术通讯,2005,17：826-828
30.周冬生,杨瑞馥.生物芯片分类及其技术原理.微生物学免疫学进展,2002a,30：101-107
31.周冬生,杨瑞馥.机械点样DNA微点阵技术及其在基因表达分析上的应用(Ⅰ).生物技术通讯,2002b,13：315-321
32.周冬生,杨瑞馥.机械点样DNA微点阵技术及其在基因表达分析上的应用(Ⅱ).生物技术通讯,2002c,13：408-414
33.朱进,唐家琪,张云,郭恒彬,陶开华.爆发流行中毒性休克综合征病原体生物学特性及鉴定.中华传染病杂志,2001,19：84-86
34.朱进,唐家琪,郭恒彬,张云,陶开华.一起猪链球菌病暴发流行的流行病学及病原学研究.解放军预防医学杂志,2000,18：257-260
35. Awano S, Ansai T, Mochizuki H, Yu W, Tanzawa K, Turner A J, Takehara T. Sequencing, expression and biochemical characterization of the Porphyromonas gingivalis pepO gene encoding a protein homologous to human endothelin-converting enzyme. FEBS Lett,1999,460:139-144
36. Allen A G, Bolitho S, Lindsay H, Khan S, Bryant C, Norton P, Ward P, Leigh J, Morgan J, Riches H, Eastty S, Maskell D. Generation and characterization of a defined mutant of Streptococcus suis lacking suilysin. Infect Immun,2001,69:2732-2735
37. Allgaier A, Goethe R, Wisselink H J, Smith H E, Valentin-Weigand P. Relatedness of Streptococcus suis Isolates of Various Serotypes and Clinical Backgrounds as Evaluated by Macrorestriction Analysis and Expression of Potential Virulence Traits, J Clin Microbiol,2001,39:445-453
38. Azuma R, Hara Y, Oonuma Y, Sugimoto C. Streptococcus R (Streptococcus suis type II) infection in pigs in Japan. National Institute of Animal Health Quarterly,1983, 23:117-126
39. Arends J P, Harwig N, Rudolphy M, Zanen H C. Carrier rate of Streptococcus suis capsular type 2 in palatine tonsils of slaughtered pigs. J Clin Microbiol,1984, 20:945-947
40. Allen A G, Lindsay H, Seilly D, Bolitho A, teters S E, Maskell D J. Identification and characterisation of hyaluronate lyase from Streptococcus suis. Microbial Pathogenesis,2004,36:327-335
41. Appleby J L, Parkinson J S, Bourret R B. Signal transduction via the multi-step phosphorelay:not necessarily a road less traveled. Cell,1996,86:845-848
42. Arends J P, Zanen H C. Meningitis caused by Streptococcus suis in humans. Rev Infect Dis,1988,10:131-137
43. Bajaj V, Lucas R L, Hwang C, Lee C A. Co-ordinate regulation of Salmonella typhimurium invasion genes by environmental and regulatory factors is mediated by control of hilA expression. Mol Microbiol.1996,22:703-714
44. Boetner A G., Binder M, Bille-Hansen V. Streptococcus suis infection in Danish pigs and experimental infection with Streptococcus suis serotype 7. Acta Pathol Microbiol Scand B,1987,95:233-239
45. Bourret R B, Borkovich K A, Simon M I. Signal transduction pathways involving protein phosphorylation in prokaryotes. Annu Rev Biochem,1991,60:401-441
46. Barrett J F, Goldschmidt R M, Lawrence L E, Foleno B, Chen R, Demers J P, Johnson S, Kanojia R, Fernandez J, Bernstein J, Licata L, Donetz A, Huang S, Hlasta D J, Macielag M J, Ohemeng K, Frechette R, Frosco M B, Klaubert D H, Whiteley J M, Wang L, Hoch J A. Antibacterial agents that inhibit two-component signal transduction systems. P Natl Acad Sci USA,1998a,95:5317-5322
47. Benga L, Fulde M, Neis C, Goethe R, Valentin-Weigand P. Polysaccharide capsule and suilysin contribute to extracellular survival of Streptococcus suis co-cultivated with primary porcine phagocytes. Vet Microbiol,2008,132:211-219
48. Beier D, Gross R. Regulation of bacterial virulence by two-component systems. Curr Opin Microbiol,2006,9:143-152
49. Barrett J F, Hoch J A. Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob Agents Chemother,1998b,42:1529-1536
50. Ba-Thein W, Lyristis M, Ohtani K, Nisbet IT, Hayashi H, et al. (1996) The virR/virS locus regulates the transcription of genes encoding extracellular toxin production in Clostridium perfringens. J Bacteriol 178:2514-2520
51. Baums C G, Kaim U, Fulde M, Ramachandran G, Goethe R, Valentin-Weigand P. Identification of a novel virulence determinant with serum opacification activity in Strptococcus suis. Infect Immun,2006,74:6154-6162
52. Berry A M, Lock R A, Thomas S M, Rajan D P, Hansman D, Paton J C. Cloning and nucleotide sequence of the Streptococcus pneumoniae hyaluronidase gene and purification of the enzyme from recombinant Escherichia coli. Infect Immun,1994, 62:1101-1108
53. Berthelot-Herault F, Morvan H, Keribin A M, Gottschalk M, Kobisch M. Production of muramidase released protein (MRP), extracellular factor (EF) and haemolysin by field isolates of Streptococcus suis capsular type 2,1/2,9,7 and 3 isolated from swine in France. Vet Res,2000,31:473-479
54. Bronner S, Monteil H, Pre'vost G. Regulation of virulence determinants in Staphylococcus aureus:complexity and applications. FEMS Microbiol Rev,2004, 28:183-200
55. Brown L N. Alpha hemolytic streptococci isolated from acute pneumonia and septicemia of Iowa swine. Proceedings of the Annual Meeting of the US Animal Health Association,1969,73:589-594
56. Busque P, Higgins R, Caya F, Quessy S. Immunisation of pigs against Streptococcus suis serotype 2 infection using a live avirulent strain. Can J Vet Res,1997,61:275-279
57. Barabote R D, Saier M H. Comparative genomic analyses of the bacterial phosphotransferase system. Microbiol Mol Biol Rev,2005,69:608-634
58. Baums C G, Valentin-Weigand P. Surface-assiociated and secreted factors of Streptococcus suis in epidemiology, pathogenesis and vaccine development. Animal Health Research Reviews,2009,20:65-83
59. Calvinho L F, Almeida R A, Oliver S P. Potential virulence factors of Streptococcus dysgalactiae associated with bovine mastitis. Vet Microbiol,1998; 61:93-110
60. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol,1992,62:S3-10
61. Chabot-Roya G, Willsonb P, Seguraa M, Lacouturea S, Gottschalk M. Phagocytosis and killing of Streptococcus suis by porcine neutrophils. Microbial Pathogenesis, 2006,41:21-32
62. Chang C, Stewart R C. The two-component system. Regulation of diverse signaling pathways in prokaryotes and eukaryotes. Plant Physiol,1998,117:723-31
63. Chanter N, Jones P W, Alexander T J L. Meningitis in pigs caused by Streptococcus suis-a speculative review. Vet Microbiol,1993,36:39-55
64. Charland N, Harel J, Kobisch M, Lacasse S, Gottschalk M. Streptococcus suis serotype 2 mutants deficient in capsular expression. Microbiology,1998,144:325-332
65. Charland N, Nizet V, Rubens C E, Kim K S, Lacouture S, Gottschalk M. Streptococcus suis serotype 2 interactions with human brain microvascular endothelial cells. Infect Immun,2000,68:637-643
66. Charland N, Kobisch M, Martineau-Doize B, Jacques M, Gottschalk M. Role of capsular sialic acid in virulence and resistance to phagocytosis of Streptococcus suis capsular type 2. FEMS Immunol Med Microbiol,1996,14:195-203
67. Chau P Y, Huang C Y, Kay R. Streptococcus suis meningitis. An important underdiagnosed disease in Hong Kong. Med J of Australia,1983,1:414-417
68. Chengappa M M, Pace L W, Williams J A, Herrin C H, Ascher S E. Efficacy of tiamulin against experimentally induced Streptococcus suis. J Am Vet Med Assoc, 1990,197:1467-1470.
69. Chengappa M M, Maddux R L, Kadel W L, Greer S C, Herren C E. Streptococcus suis infection in pigs:incidence and experimental reproduction of the syndrome. In: M.W. Vorhies (ed.), Proceedings of the American Association of Veterinary Laboratory Diagnosticians, Louisville,1986,29:25-38
70. Chen C, Tang J, Dong W, Wang C, Feng Y, Wang J, Zheng F, Pan X, Liu D, Li M, Song Y, Zhu X, Sun H, Feng T, Guo Z, Ju A, Ge J, Dong Y, Sun W, Jiang Y, Wang J, Yan J, Yang H, Wang X, Gao GF, Yang R, Wang J, Yu J. A glimpse of streptococcal toxic shock syndrome from comparative genomics of S. suis 2 Chinese isolates. PLoS ONE,2007,2:e315
71. Christensen P, Kronvall G. Capacity of group A, B, C, D, and G streptococci to agglutinate sensitized sheep red cells. Acta Pathologica et Microbiologica Scandinavica,1974,82:19-24
72. Clifton-Hadley F A. The epidemiology, diagnosis, treatment and control of Streptococcus suis type 2 infection. In:J.D. McKean (ed.). Proceedings of the American Association of Swine Practitioners, Minneapolis,1986,471-491
73. Clifton-Hadley F, Alexander T. Diagnosis of Streptococcus suis infection in pigs. In: E. Boden(ed.), Swine Practice,1991,115-126
74. Cock P J, Whitworth D E. Evolution of gene overlaps:relative reading frame bias in prokaryotic two-component system genes. J Mol Evol,2007a,64:457-462
75. Cock P J, Whitworth D E. Evolution of prokaryotic two-component system signaling pathways:gene fusions and fissions. Mol Biol Evol,2007b,24:2355-2357
76. Cotter P A, Jones A M. Phosphorelay control of virulence gene expression in Bordetella. Trends Microbiol,2003,11:367-373
77. Courtney H S, Li Y, Dale JB, Hasty D L. Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. Infect Immun, 1994,62:3937-3946
78. Daniely D, Portnoi M, Shagan M, Porgador A, Givon-Lavi N, Ling E, Dagan R & Nebenzahl Y M. Pneumococcal 6-phosphogluconate-dehydrogenase, a putative adhesin, induces protective immune response in mice. Clin Exp Immunol,2006, 144:254-263
79. del Campo Sepulveda E M, Altman E, Kobisch M, D'Allaire S, Gottschalk M. Detection of antibodies against Streptococcus suis capsular type 2 using a purified capsular polysaccharide antigen-based indirect ELISA. Vet Microbiol,1996,52:113-125 137.
80. de Greeff A, van Alphen L, Smith H E. Selection of Recombinant Antibodies Specific for Pathogenic Streptococcus suis by Subtractive Phage Display. Infect Immun,2000,68:3949-3955
81. de Greeff A, Buys H, Verhaar R, Dijkstra J, van Alphen L, Smith H E. Contribution of Fibronectin-Binding Protein to Pathogenesis of Streptococcus suis Serotype 2. Infect Immun,2002,70:1319-1325
82. Denholm I, Sawicki R M, Farnham A W. Factors affecting resistance to insecticides in houseflies, Musca domestica L. (Diptera:Muscidae). Ⅳ. The population biology of flies on animal farms in south-eastern England and its implications for the management of resistance. B Entomol Res,1985,75:143-158
83. Devriese L A, Sustronck B, Maenhouth T, Haesebrouck F. Streptococcus suis meningitis in a horse. Vet Rec,1990,127:68
84. Devriese L A, Haesebrouck F, de Herdt P, Dom P, Ducatelle R, Desmidt M, Messier S, Higgins R. Streptococcus suis infections in birds. Avian Pathol,1994,23:721-724
85. Dominguez-Punaro M C, Segura M, Plante M M, Lacouture S, Rivest S, Gottschalk M. Streptococcus suis serotype 2, an important swine and human pathogen, induces strong systemic and cerebral inflammatory responses in a mouse model of infection. J Immunol 2007,179:1842-1854
86. Elliott S D, Clifton-Hadley F, Tai J. Streptococcal infection in young pigs. V. An immunogenic polysaccharide from Streptococcus suis type 2 with particular reference to vaccination against streptococcal meningitis in pigs. J Hyg (Lond),1980, 85:275-285
87. Elliott S D, Tai J Y. The type specific polysaccharide of Streptococcus suis. J Exp Med,1978,148:1699-1704
88. Enright M R, Alexander T J L, Clifton-Hadley F A. Role of house￡ies (Musca domestica) in the epidemiology of Streptococcus suis type 2. Vet Rec,1987,121:132-133
89. Fabret C, Hoch J A. A two-component signal transduction system essential for growth of Bacillus subtilis:implications for anti-infective therapy. J Bacteriol,1998, 180:6375-6383
90. Fabret C, Feher V A, Hoch J A. Two-component signal transduction in Bacillus subtilis:how one organism sees its world. J Bacteriol,1999,181:1975-1983
91. Feng Y, Zheng F, Pan X, Sun W, Wang C, et al. Existence and characterization of allelic variants of Sao, a newly identified surface protein from Streptococcus suis. FEMS Microbiol Lett,2007,275:80-88
92. Federle M J, McIver K S, Scott J R. A response regulator that represses transcription of several virulence operons in the group A Streptococcus. J Bacteriol,1999, 181:3649-3657
93. Field H I, Buntan D, Done J T. Studies on piglet mortality. I. Streptococcal meningitis and arthritis. Vet Rec,1954,66:454-455
94. Forst S, Inouye M. Environmentally regulated gene expression for membrane proteins in Escherichia coli. Annu Rev Cell Biol,1988,4:21-42
95. Fukuchi K, Kasahara Y, Asai K, Kobayashi K, Moriya S, Ogasawara N. The essential two-component regulatory system encoded by yycF and yycG modulates expression of the ftsAZ operon in Bacillus subtilis. Microbiology,2000,146:1573-1583
96. Francois B, Gissot V, Ploy M C, Vignon P. Recurrent Due to Streptococcus suis. J Clin Microbiol,1998,36:2395
97. Frishman D, Mironov A, Mewes H W, Gelfand M. Combining diverse evidence for gene recognition in completely sequenced bacterial genomes. Nucleic Acids Res, 1998,26:2941-2947
98. Froeliger E H, Oetjen J, Bond J P, Fives-Taylor P. Streptococcus parasanguis pepO encodes an endopeptidase with structure and activity similar to those of enzymes that modulate peptide receptor signaling in eukaryotic cells. Infect Immun,1999, 67:5206-5214
99. Galina L, Vecht U, Wisselink H J, Pijoan C. Prevalence of various phenotypes of Streptococcus suis isolated from swine in the U.S.A. based on the presence of muraminidase-released protein and extracellular factor. Can J Vet Res,1996,60:72-74
100. Galcheva-Gargova Z, Derijard B, Wu I H, Davis R J. An osmosensing signal transduction pathway in mammalian cells. Science,1994,265:806-808
101. Giammarinaro P, Sicard M, Gasc A. Genetic and physiological studies of the CiaH-CiaR two-component signal-transducing system involved in cefotaxime resistance and competence of Streptococcus pneumoniae. Microbiol,1999,145:1859-1869
102. Gogolewski R P, Cook R W, O'Connell C J. Streptococcus suis serotypes associated with disease in weaned pigs. Aust Vet J,1990,67:202-204
103. Gottschalk M, Higgins R, Jacques M, Mittal K R, Henrichsen J. Description of 14 new capsular types of Streptococcus suis. J Clin Microbiol,1989,27:2633-2636
104. Gottschalk M, Higgins R, Jacques M, Beaudoin M, Henrichsen J. Isolation and characterization of Streptococcus suis capsular types 9-22. J Vet Diagn Invest,1991a, 3:60-65
105. Gottschalk M, S egura M. The pathogenesis of the meningitis caused by Streptococcus suis:the unresolved questions. Vet Microbiol,2000,76:259-272
106. Gottschalk M, Higgins R, Jacques M, Beaudoin M, Henrichsen J. Characterization of six new capsular types (23 through 28) of Streptococcus suis. J Clin Microbiol, 1991b,29:2590-2594
107. Granlund M, Oberg L, Scum M, Norgren M. Identification of a novel insertion element, IS 1548, in group B streptococci, predominantly in strains causing endocarditis. J Infect Dis,1998,177:967-976
108. Graham M R, Smoot L M, Migliaccio C A, Virtaneva K, Sturdevant D E, Porcella S F, Federle M J, Adams G J, Scott J R, Musser J M. Virulence control in group A Streptococcus by a two-component gene regulatory system:global expression profiling and in vivo infection modeling. P Natl Acad Sci USA,2002,99:13855-13860
109. Graveline R, Segura M, Radzioch D, Gottschalk M. TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. Int Immunol,2007,19:375-389
110. Guise H J, Penny R H C, Duthie A N S. Streptococcal meningitis in pigs. Vet Rec, 1985,117:43-44
111. Guenzi E, Gasc A M, Sicard M A, Hakenbeck R. A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae. Mol Microbiol,1994,12:505-515
112. Goulielmos G N, Eliopoulos E, Loukas M, Tsakas S. Functional constraints of 6-phosphogluconate dehydrogenase(6-PGD) based on sequence and structural information. J Mol Evol,2004,59:358-371
113. Gunther B, Ozegowski J H, Kohler W. Occurrence of extracellular hyaluronic acid and hyaluronate lyase in streptococci of groups A, B, C, and G. Zentralbl Bakteriol, 1996,285:64-73
114. Heidt M C, Mohamed W, Hain T, Vogt P R, Chakraborty T, Domann E. Human Infective Endocarditis Caused by Streptococcus suis Serotype 2. J Clin Microbiol, 2005,43:4898-4901
115. Heath A, DiRita V J, Barg N L, Engleberg N C. A twocomponent regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infect Immun, 1999,67:5298-5305
116. Higgins R, Gottschalk M. Distribution of Streptococcus suis capsular types in 1994. Can Vet J,1995,36:320
117. Higgins R, Gottschalk M. Quebec. Distribution of Streptococcus suis capsular types in Canada in 1991, Can Vet J,1992,33:406
118. Hoie S, Falk K, Lium B M. An abattoir survey of pneumonia and pleuritis in slaughter weight swine from 9 selected herds. Ⅳ. Bacteriological findings in chronic pneumonic lesions. Acta Vete Scand,1991,32:395-402
119. Holden M T G, Hauser H, Sanders M,Ngo T H, Cherevach I, Cronin A, Goodhead I, Mungall Ka, Quail M A, Price C, Rabbinowitsch E, Sharp S, Croucher N J, Chieu T B, Mai NTH, Diep T S, Chinh N T, Kehoe M, Leigh J A, Ward P N, Dowson C G, Whatmore A M, Chanter N, Iversen P, Gottschalk M, Slater J D, Smith H E, Spratt B G,Xu J, Ye C, Bentley S, Barrell BG, Schultsz C, Maskell D J, Parkhill J. Rapid Evolution of Virulence and Drug Resistance in the Emerging Zoonotic Pathogen Streptococcus suis. PLoS ONE,2009,4:e6072
120. Holt M E, Enright M R, Alexander T J. Immunisation of pigs with live cultures of Streptococcus suis type 2. Rev Vet Sci,1988,45:349-352
121. Holt M E, Enright M R, Alexander T J. Immunisation of pigs with killed cultures of Streptococcus suis type 2. Rev Vet Sci,1990,48:23-27
122. Homer K, Shain H, Beighton D. The role of hyaluronidase in growth of Streptococcus intermedius on hyaluronate. Adv Exp Med Biol,1997,418:681-683
123. Homer K A, Denbow L, Whiley R A, Beighton D. Chondroitin sulfate depolymerase and hyaluronidase activities of viridans streptococci determined by a sensitive spectrophotometric assay. J Clin Microbiol,1993,31:1648-1651
124. Hommez J, Castryck L A, Henrichsen J. Prevalence of Streptococcus suis and methods of identification. In:M. Pensaert, J. Hoorens, P. Lampo, P. Bonte,W. Coussement and P. Debouck (eds). Proceedings of the International Pig Veterinary Society Congress, Gent,1984,8:134
125. Hommez J, Willepit J, Cassimon 0, Castryck F, Ceyssens K, Devriese L A. Streptococcus suis and other streptococcal species as a cause of extramammary infection in ruminants. Vet Rec,1988,123:626-627
126. Huang YT, Teng LJ, Ho SW, Hsueh PR. Streptococcus suis infection. J Microbiol Immunol Infect,2005,58:306-313
127. Hynes W L, Walton S L. Hyaluronidases of Gram-positive bacteria. FEMS Microbiol Lett,2000,183:201-207
128. Iglarz M, Schiffrin E L. Role of endothelin-1 in hypertension. Curr Hypertens Rep, 2003,5:144
129. Jacobs A A C, Loeffen P L W, van den Berg A J G, Storm P K. Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. Infect Immun,1994,62:1742-1748
130. Jacobs A A C, van den Berg A J G, Loeffen P L W. Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis. Vet Rec,1996,139:225-228
131. Jensen J, van Dorssen C A. Meningo-encephalitis bij vafkens door streptococcen. Tijdschr Diergeneesk,1951,76:815-832
132. Jiang S M, Cieslewicz M J, Kasper D L, Wessels M R. Regulation of virulence by a two-component system in group B streptococcus. J Bacteriol,2005,187:1105-1113
133. Joh D, Wann E R W, Kreikemeyer B, Speziale P, Hook M. Role of fibronectin-binding MSCRAMMS in bacterial adherence and entry into mammalian cells. Matrix Biol,1999,18:211-223
134. Kataoka Y, Sugimoto C, Nakazawa M, Morozuni T, Kashiwazaki M. The epidemiological studies of Streptococcus suis infections in Japan from 1987 to 1991. J Vet Med Sci,1993,55:623-626
135. Kay R, Cheng A F, Tse C Y. Streptococcus suis infection in Hong Kong. Quarterly J Med,1995,88:39-47
136. King S J, Heath P J, Luque I, Tarradas C, Dowson C G, Whatmore A M. Distribution and Genetic Diversity of Suilysin in Streptococcus suis Isolated from Different Diseases of Pigs and Characterization of the Genetic Basis of Suilysin Absence. Infect Immun,2001,69:7572-7582
137. Koehne G, Maddux F L, Cornell W D. Lancefield group R streptococci associated with pneumonia in swine. Am J Vet Res,1979,40:1640-1641
138. Korth P, Bohle R M, Corvol P, Pinet F. Cellular distribution of endothelin converting enzyme-1 in human tissues. J Histochem Cytochem,1999,47:447
139. Kox L F F, Wosten M M S M, Groisman E A. A small protein that mediates the activation of a two-component system by another two-component system. EMBO J, 2000,19:1861-1872
140. Kuchma S L, Connolly J P, O'Toole G A. A three-component regulatory system regulates biofilm maturation and type III secretion in Pseudomonas aeruginosa. J Bacteriol,2005,187:1441-1454
141. Lalonde M, Segura M, Lacouture S, Gottschalk M. Interactions between Streptococcus suis serotype 2 and different epithelial cell lines. Microbiol,2000, 146:1913-1921
142. Lanie J A, Ng W L, Kazmierczak K M, Andrzejewski T M, Davidsen T M, Wayne K J, Tettelin H, Glass J I, Winkler M E. Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J Bacteriol,2007,189:38-51
143. Lamy M C, Zouine M, Fert J, Vergassola M, Couve E, Pellegrini E, Glaser P, Kunst F, Msadek T, Trieu-Cuot P, Poyart C.CovS/CovR of group B streptococcus:a two-component global regulatory system involved in virulence. Mol Microbiol,2004, 54:1250-1268
144. Li Y H, Lau P C, Tang N, Svensater G, Ellen R P, Cvitkovitch D G Novel two-component regulatory system involved in biofilm formation and acid resistance in Streptococcus mutans. J Bacteriol,2002,184:6333-6342
145. Li M, Wang C, Feng Y, Pan X, Cheng G, Wang J, Ge J, Zheng F, Cao M, Dong Y, Liu D, Wang J, Lin Y, Du H, Gao GF, Wang X, Hu F, Tang J. SalK/SalR, a two component signal transduction system, is essential for full virulence of highly invasive Streptococcus suis serotype 2. PLoS ONE,2008,3:e2080
146. Ling E W Y, Noya F J D, Ricard G, Beharry K, Mills E L, Aranda J V. Biochemical mediators of meningeal inflammatory response to group B Streptococcus in the newborn piglet model. Pediatr Res,1995,38:981-987
147. Liang X, Zheng L, Landwehr C, Lunsford D, Holmes D, Ji Y. Global regulation of gene expression by ArlRS, a two-component signal transduction regulatory system of Staphylococcus aureus. J Bacteriol,2005,187:5486-5492
148. Lyon G J, Mayville P, Muir T W, Novick R P. Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. P Natl Acad Sci USA, 2000,97:13330-13335
149. Lunsford R D, London J. Natural genetic transformation in Streptococcus gordonii: comX imparts spontaneous competence on strain wicky. J Bacteriol,1996, 178:5831-5835
150. Lun S, Perez-Casal J, Connor W, Willson P J. Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2. Microb Pathog.2003,34:27-37
151. Maeda T, Wurgler-Murphy S M, Saito H. A two-component system that regulates an osmosensing MAP kinase cascade in yeast. Nature,1994,369:242-245
152. Maeda T, Takekawa M, Saito H. Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor. Science,1995,269:554-558
153. Martin P K, Li T, Sun D, Biek D P, Schmid M B. Role in cell permeability of an essential two-component system in Staphylococcus aureus. J Bacteriol,1999, 181:3666-3673
154. Marcelo G, Mariela S. The pathogenesis of the meningitis caused by Streptococcus suis:the unresolved questions. Vet Microbiol,2000,76:259-272
155. Mascher T, Heintz M, Zahner D, Merai M, Hakenbeck R. The CiaRH system of Streptococcus pneumoniae prevents lysis during stress induced by treatment with cell wall inhibitors and mutations in pbp2x involved in beta-lactam resistance. J Bacteriol,2006,188:1959-1968
156. McKessar S J, Hakenbeck R. The Two-Component Regulatory System TCS08 Is Involved in Cellobiose Metabolism of Streptococcus pneumoniae R6. J Bacteriol, 2007,189:1342-1350
157. Mascher T, Merai M, Balmelle N, de Saizieu A, Hakenbeck R. The Streptococcus pneumoniae. cia regulon:CiaR target sites and transcription profile analysis. J Bacteriol,2003,185:60-70
158. Mierau I, Tan P S, Haandrikman A J, Mayo B, Kok J, Leenhouts K J, Konings W N, Venema G. Cloning and sequencing of the gene for a lactococcal endopeptidase, an enzyme with sequence similarity to mammalian enkephalinase. J Bacteriol,1993, 175:2087-2096
159. Miller A A, Engleberg N C, DiRita V J. Repression of virulence genes by phosphorylation-dependent oligomerization of CsrR at target promoters in S.pyogenes. Mol Microbiol,2001,40:976-990
160. McCluskey J, Hinds J, Husain S, Witney A, Mitchell T J. A two-component system that controls the expression of pneumococcal surface antigen A (PsaA) and regulates virulence and resistance to oxidative stress in Streptococcus pneumoniae. Mol Microbiol,2004,51:1661-1675
161. Mizuno T, Mizushima S. Signal transduction and gene regulation through the phosphorylation of two regulatory components:the molecular basis for the osmotic regulation of the porin genes. Mol Microbiol,1990,4:1077-1082
162. Moss J E, Fisher P E, Vick B, Groisman E A, Zychlinsky A. The regulatory protein PhoP controls susceptibility to the host inflammatory response in Shigella flexneri. Cell Microbiol,2000,2:443-52
163. Mouslim C, Delgado M, Groisman E A. Activation of the RcsC/YojN/RcsB phosphorelay system attenuates Salmonella virulence. Mol Microbiol,2004,54:386-395
164. Mwaniki C G, Robertson I D, Trott D J, Atyeo R F, Lee B J, Hampson D J. Clonal analysis and virulence of Australian isolates of Streptococcus suis type 2. Epidemiol Infect,1994,113:321-334
165. Navarre W W, Halsey T A, Walthers D, Frye J, McClelland M, Potter J L, Kenney L J, Gunn J S, Fang F C, Libby S J. Co-regulation of Salmonella enterica genes required for virulence and resistance to antimicrobial peptides by SlyA and PhoP/PhoQ. Mol Microbiol,2005,56:492-508
166. Naidoo V, Naidoo S, Mahabeer R, Raidoo D M. Cellular distribution of the endothelin system in the human brain. J Chem Neuroanat,2004,27:87
167. Ng W L, Tsui H C, Winkler M E. Regulation of the pspA virulence factor and essential pcsB murein biosynthetic genes by the phosphorylated VicR (YycF) response regulator in Streptococcus pneumoniae. J Bacteriol,2005,187:7444-7459
168. Novick R P. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol,2003,48:1429-1449
169. Norton P M, Rolph C, Ward P N, Bentley R W, Leigh J A. Epithelial invasion and cell lysis by virulent strains of Streptococcus suis is enhanced by the presence of suilysin. FEMS Immunol Med Microbiol,1999,26:25-35
170. Oetjen J, Fives-Taylor P, Froeliger E. Characterization of a streptococcal endopeptidase with homology to human endothelin-converting enzyme. Infect Immun,2001,69:58-64
171. Osaki M, Takamatsu D, Shimoji Y, Sekizaki T. Characterization of Streptococcus suis Genes Encoding Proteins Homologous to Sortase of Gram-Positive Bacteria. J Bacteriol,2002,184:971-982
172. Osaki M, Takamatsu D, Shimoji Y, Sekizaki T. Allelic variation in srtAs of Streptococcus suis strains. FEMS Microbiol Lett,2003,219:195-201
173. Ossowicz C J, Pointon A M, Davies P R. Streptococcus suis isolated from pigs in South Australia. Aust Vet J,1989,66:377-378
174. Ota I M, Varshavsky A. A yeast protein similar to bacterial two-component regulators. Science,1993,262:566-569
175. Pan X, Ge J, Li M, Wu B, Wang C, Wang J, Feng Y, Yin Z, Zheng F, Cheng G, Sun W, Ji H, Hu D, Shi P, Feng X, Hao X, Dong R, Hu F, Tang J. The Orphan Response Regulator CovR:a Globally Negative Modulator of Virulence in Streptococcus suis Serotype 2. J Bacteriol,2009,191:2601-2612
176. Parkinson J S, Kofoid E C. Communication modules in bacterial signaling proteins. Annu Rev Genet,1992,26:71-112
177. Pearson W R, Lipman D J. Improved Tools for Biological Sequence Comparison. P Natl Acad Sci USA.1988,85:2444-2448
178. Pedroli S, Kobisch M, Beauchet O, Chaussinand J P, Lucht F. Streptococcus suis bacteremia. Presse Med,2003,32:599-601
179. Perch B, Kristjansen P, Skadhauge K. Group R Streptococci pathogenic for man: two cases of meningitis and one fatal case of sepsis. Acta Pathol Microbiol Scand, 1968,74:69-76
180. Perch B, Pedersen K B, Henrichsen J. Serology of capsulated streptococci pathogenic for pigs:six new serotypes of Streptococcus suis. J Clin Microbiol,1983, 17:993-996
181. Pestova E V, Havarstein L S, Morrison D A. Regulation of competence for genetic transformation in Streptococcus pneumoniae by an auto-induced peptide pheromone and a two-component regulatory system. Mol Microbiol,1996,21:853-862
182. Pritchard D G, Lin B, Willingham T R, Baker J R. Characterization of the group B streptococcal hyaluronate lyase. Arch Biochem Biophys,1994,315:431-437
183. Posas F, Wurgler-Murphy S M, Maeda T, Witten E A, Thai T C, Saito H. Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the SLN1-YPD1-SSK1 "two-component" osmosensor. Cell,1996,86:865-875
184. Postma P W, Lengeler J W, Jacobson G R. Phosphoenolpyruvate:carbohydrate phosphotransferase systems of bacteria. Microbiol Rev,1993,57:543-594
185. Power S B. Streptococcus suis type 2 infection in pigs. Vet Rec,1978,102:215-216
186. Prieto C, Pena J, Suarez P, Imaz M, Castro J M. Isolation and distribution of Streptococcus suis capsular types from diseased pigs in Spain. Zentralblatt fur Veterinarmedizin, Reihe B,1993,40:544-548
187. Quessy S, Busque P, Higgins R, Jacques M, Dubreuil J D. Description of an albumin binding activity for Streptococcus suis serotype 2. FEMS Microbiol Lett, 1997,147:245-250
188. Quessy S, Dubreuil D, Higgins R. Immunization of mice against Streptococcus suis type 2 infection using a live avirulent strain. Can J Vet Res,1994,58:299-301
189. Rawlings N D, Barrett A J. Evolutionary families of metallopeptidases. Methods Enzymol,1995,248:183-228
190. Reams R Y, Harrington D D, Glickman L T, Thacker H L, Bowersock T L. Fibrinohemorrhagic pneumonia in pigs naturally infected with Streptococcus suis. J Vet Diagn Invest,1995,7:406-408
191. Robertson I D, Blackmore D K. Prevalence of Streptococcus suis types 1 and 2 in domestic pigs in Australia and New Zealand. Vet Rec,1989,124:391-394
192. Robertson I D, Blackmore D K. Experimental studies on the comparative infectivity and pathogenicity of Streptococcus suis type 2. Ⅱ. Porcine and human isolates in laboratory animals. Epidemiol Infect,1990,105:479-484
193. Rolland K, Marois C, Siquier V, Cattier B, Quentin R. Genetic features of Streptococcus agalactiae strains causing severe neonatal infections, as revealed by pulsed-field gel electrophoresis and hylB gene analysis. J Clin Microbiol,1999, 37:1892-1898
194. Rosenkranz M, Elsner H A, Sturenburg H J, Weiller C, Rother J, Sobottka I. Streptococcus suis meningitis and septicemia contracted from a wild boar in Germany. J Neurol,2003,250:869-870
195. Sanford S E. Gross and histopathological findings in unusual lesions caused by Streptococcus suis in pigs.Ⅱ. Central nervous system lesions. Can J Vet Res,1987, 51:486-489
196. Sanford S E. Streptococcus suis:a strategic update. In:Proceedings of the Annual Meeting of the American Association of Swine Practitioners, Des Moines,1989, 193-195
197. Sanford S E, Tilker M E. Streptococcus suis type Ⅱ-associated diseases in swine: observations of a one-year study. J Am Vet Med Asso,1982,181:673-676
198. Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A, Tuomanen E. The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J Exp Med,1990,171:439-448
199. Schaufuss P, Sting R, Schaeg W, Blobel H. Isolation and characterization of hyaluronidase from Streptococcus uberis. Zentralbl Bakteriol,1989,271:46-53
200. Seddon S V, Hemingway I, Borriello S P. Hydrolytic enzyme production by Clostridium difficile and its relationship to toxin production and virulence in the hamster model. J Med Microbiol,1990,31:169-74
201. Segers R P, Kenter T, de Haan L A, Jacobs A A. Characterisation of the gene encoding suilysin from Streptococcus suis and expression in field strains. FEMS Microbiol Lett,1998,167:255-261
202. Segura M, Cleroux P, Gottschalk M. Streptococcus suis and group B Streptococcus differ in their interactions with murine macrophages. FEMS Immunol Med Microbiol,1998,21:189-195
203. Segura M, Gottschalk M. Extracellular virulence factors of streptococci associated with animal diseases. Front Biosci,2004,9:1157-1188
204. Segura M, Gottschalk M. Streptococcus suis interactions with the murine macrophage cell line J774:adhesion and cytotoxicity. Infect Immun,2002,70:4312-4322
205. Segura M, Stankova J, Gottschalk M. Heat-Killed Streptococcus suis Capsular Type 2 Strains Stimulate Tumor Necrosis Factor Alpha and Interleukin-6 Production by Murine Macrophages. Infect Immun,1999,67:4646-4654
206. Serhir B, Dubreuil D, Higgins R, Jacques M. Purification and characterization of a 52-kilodalton immunoglobulin G-binding protein from Streptococcus suis capsular type 2. J Bacteriol,1995,177:3830-3836
207. Serhir B, Higgins R, Foiry B, Jacques M. Detection of immunoglobulin-binding proteins in Streptococcus suis. J Gen Microbiol,1993,139:2953-2958
208. Sessa W C, Kaw S, Hecker M, Vane J R.The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Bioph Res Co,1991,174:613
209. Sihvonen L, Kurl D N, Henrichsen J. Streptococcus suis isolated from pigs in Finland. Acta Vet Scand,1988,29:9-13
210. Smith H E, Buijs H, de Vries R R, Wisselink H J, Stockhofe-Zurwieden N, Smits M A. Environmentally regulated genes of Streptococcus suis:identification by the use of iron-restricted conditions in vitro and by experimental infection of piglets. Microbiology,2001,147:271-280
211. Smith H E, Damman M, van der Velde J, Wagenaar F, Wisselind H J, Stockhofe-zurwieden N, Smits M A. Identification and Characterization of the cps Locus of Streptococcus suis Serotype 2:the Capsule Protects against Phagocytosis and Is an Important Virulence Factor. Infect Immun,1999,67:1750-1756
212. Smith H E, de Vries R, van't Slot R, Smits M A. The cps locus of Streptococcus suis serotype 2:genetic determinant for the synthesis of sialic acid. Microb Pathog, 2000,29:127-134
213. Smith H E, Vecht U, Wisselink H J, Stockhofe-Zurwieden N, Biermann Y, Smits M A. Mutants of Streptococcus suis types 1 and 2 impaired in expression of muramidase-released protein and extracellular protein induce disease in newborn germfree pigs. Infect Immun,1996,64:4409-4412
214. Smith H E, Vecht U, Gielkens A L, Smits M A. Cloning and nucleotide sequence of the gene encoding the 136-kilodalton surface protein (muramidase-released protein) of Streptococcus suis type 2. Infect Immun,1992,60:2361-2367
215. Smolen P, Baxter D A, Byrne J H. Modeling transcriptional control in gene networks-methods, recent results, and future directions. Bull Math Biol,2000, 62:247-292
216. Sorensen N S, Tegtmeier C, Andresen L O, Pineiro M, Toussaint M J M, Campbell F M, Lampreave F, Heegaard P M H. The porcine acute phase protein response to acute clinical and subclinical experimental infection with Streptococcus suis. Vet Immunol Immunopathol,2006,113:157-168
217. Sprenger H, Rosler A, Tonn P, Braune H J, Huffmann G, Gemsa D. Chemokines in the cerebrospinal fluid of patients with meningitis. Clin Immunol Immunopathol, 1996,80:155-161
218. Staats J J, Feder I, Okwumabua O, Chengappa M M. STREPTOCOCCUS SUIS: PAST AND PRESENT. Vet Res Commun,1997,21:381-407.
219. Staats J J, Plattner B L, Stewart G C, Changappa M M. Presence of the Streptococcus suis suilysin gene and expression of MRP and EF correlates with high virulence in Streptococcus suis type 2 isolates. Vet Microbiol,1999,70:201-211
220. Staats J J, Plattner B L, Nietfeld J, Dritz S, Chengappa M M. Use of ribotyping and hemolysin activity to identify highly virulent Streptococcus suis type 2 isolates. J Clin Microbiol,1998,36:15-19
221. Stephenson K, Yamaguchi Y, Hoch JA. The mechanism of action of inhibitors of bacterial two-component signal transduction systems. J Biol Chem,2000, 275:38900-38904
222. Stock J B, Ninfa A J, Stock A M. Protein phosphorylation and regulation of adaptive responses in bacteria. Microbiol Rev,1989,53:450-490
223. Stock J B, Stock A M, Mottonen J M. Signal transduction in bacteria. Nature,1990, 344:395-400
224. Strangmann E, Froleke H, Kohse K P. Septic shock caused by Streptococcus suis: Case report and investigation of a risk group. Int J Hyg Environ Health,2002, 205:385-392
225. Takamatsu D, Osaki M, Sekizaki T. Construction and characterization of Streptococcus suis-Escherichia coli shuttle cloning vectors. Plasmid,2001,45:101-113
226. Takamatsu D, Osaki M, Sekizaki T. Evidence for Lateral Transfer of the Suilysin Gene Region of Streptococcus suis. J Bacterial,2002,184:2050-2057
227. Takamatsu D, Osaki M, Tharaviehitkul P, Takai S, Sekizaki T. Allelic variation and prevalence of serum opacity factor among the Streptococcus suis population. J Med Microbiol,2008,57:488-494
228. Tang J, Wang C, Feng Y, Yang W, Song H, Chen Z, Yu H, Pan X, Zhou X, Wang H, Wu B,Wang H, Zhao H, Lin Y, Yue J, Wu Z, He X, Gao F, Khan A H, Wang J, Zhao G, Wang Y, Wang X, Chen Z, Gao GF. Streptococcal toxic shock syndrome caused by Streptococcus suis serotype 2. PLoS Med,2006,3:e151
229. Tarradas C, Arenas A, Maldonado A, Luque I, Miranda A, Perea A. Identfication of Streptococcus suis isolated from swine:proposal for biochemical parameters. J Clin Microbiol,1994,32:578-580
230. Tarradas C, Borge C, Arenas A, Maldonado A, Astorga R, Miranda A, Luque I. Suilysin production by Streptococcus suis isolated from diseased and healthy carrier pigs in Spain. Vet Rec,2001a,148:183-184
231. Tarradas C, Luque I, de Andres D, Abdel-Aziz Shahein Y, Pons P, Gonzalez F, Borge C, Perea A. Epidemiological relationship of human and swine Streptococcus suis isolates. J Vet Med B Infect Dis Vet Public Health,2001b,48:347-355
232. Throup J P, Koretke K K, Bryant A P, Ingraham K A, Chalker A F, Ge Y, Marra A, Wallis N G, Brown J R, Holmes D J, Rosenberg M, Burnham M K. A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol Microbiol,2000,35:566-576
233. Townsend GC, Scheld WM. Microbe-endothelium interactions in blood-brain barrier permeability during bacterial meningitis. ASM News,1995,61:294-298
234. Trottier S, Higgins R, Brochu G, Gottschalk M. A case of human endocarditis due to Streptococcus suis in North America. Rev Infect Dis,1991,13:1251-1252
235. Tuomanen E. Entry of pathogens into the central nervous system. FEMS Microbiol Rev,1996,18:289-299
236. Ulijasz A T, Andes D R, Glasner D R, Weisblum B. Regulation of iron transport in Streptococcus pneumoniae by RitR, an orphan response regulator. J Bacteriol,2004, 186:8123-8136
237. Vadeboncoeur N, Segura M, Al-Numani D, Vanier G, Gottschalk M. Proinflammatory cytokine and chemokine release by human brain micro vascular endothelial cells stimulated by Streptococcus suis serotype 2.FEMS Immun Med Microbiol,2003,35:49-58
238. Vanier G, Segura M, Fried P, Lacouture S, Gottschalk M. Invasion of Porcine Brain Microvascular Endothelial Cells by Streptococcus suis Serotype 2. Infect Immun, 2004,72:1441-1449
239. Vanier G, Sekizaki T, Dominguez-Punaro M C, Esgleas M, Osaki M, Takamatsu D, Segura M, Gottschalk M. Disruption of srtA gene in Streptococcuc suis results in decreased interactions with endothelial cells and extracellular matrix proteins. Vet Microbiol,2008,127:417-424
240. Varughese K I. Molecular recognition of bacterial phosphorelay proteins. Curr Opin Microbiol,2002,5:142-148
241. Vatter H, Mursch K, Zimmermann M, Zilliken P, Kolenda H, Seifert V, Schilling L. Endothelin-converting enzyme activity in human cerebral circulation. Neurosurgery, 2002,51:445
242. Vela A I, Goyache J, Tarradas C, Luque I, Mateos A, Moreno M A, Borge C, Perea J A, Dominguez L, Fernandez-Garayzabal J F. Analysis of genetic diversity of Streptococcus suis clinical isolates from pigs in Spain by pulsed-field gel electrophoresis. J Clin Microbiol,2003,41:2498-2502
243. Vecht U, Wisselink H J, Jellema M L, Smith H E. Identification of two proteins associated with virulence of Streptococcus suis type 2. Infect Immun,1991,59:3156-3162
244. Vecht U, Wisselink H J, van Dijk J E, Smith H E. Virulence of Streptococcus suis type 2 strains in newborn germfree pigs depend on phenotype. Infect Immun,1992, 60:550-556
245. Vecht U, Arends J P, van der Molen E J, van Leengoed L A M G.. Differences in virulence between two strains of Streptococcus suis type 2 after experimentally induced infection of newborn germfree pigs. Am J Vet Res,1989,50:1037-1043
246. Verhoef J, Mattsson E. The role of cytokines in gram-positive bacterial shock. Trends Microbiol,1995,3:136-140
247. Wang C, Li M, Feng Y, Zheng F, Fong Y, Pan, X, Cheng G, Dong R, Hu D, Feng X, Ge J, Liu D, Wang J, Gao M, Hu F, Tang J. The involvement of sortase A in high virulence of STSS-causing Streptococcus suis serotype 2. Arch Micorbiol,2009, 191:23-33
248. West A H, Stock A M. Histidine kinases and response regulator proteins in two-component signaling systems. Trends Biochem Sci,2001,26:369-376
249. Williams A E, Blakemore W F, Alexander T J L. A murine model of Streptococcus suis type 2 meningitis in pigs. Res Vet Sci,1988,45:394-399
250. Wilson S M, Norton P, Haverson K, Leigh J, Bailey M. Interactions between Streptococcus suis serotype 2 and cells of the myeloid lineage in the palatine tonsil of the pig. Vet Immunol Immunop.2007,117:116-23
251. Windsor R S, Elliott S D. Streptococcal infection in young pigs. Ⅳ. An outbreak of streptococcal meningitis in weaned pigs. Journal of Hygiene,1975,75:69-78
252. Windsor R S. Meningitis in pigs caused by Streptococcus suis type 2. Vet Rec,1977, 101:378-379
253. Wisselink H J, Smith H E, Stockhofe-Zurwieden N, Peperkamp K, Vecht U. Distribution of capsular types and production of muramidase-released protein (MRP) and extracellular factor (EF) of Streptococcus suis strains isolated from diseased pigs in seven European countries. Vet Microbiol,2000,74:237-248
254. Wisselink H J, Vecht U, Stockhofe-Zurwieden N, Smith H E. Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine. Vet Rec,2001, 148:473-477
255. Wisselink H J, Stockhofe-Zurwieden N, Hilgers L, Smith H E. Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of Streptococcus suis type 2. Vet Microbiol,2002,84:155-168
256. Wurgler-Murphy S M, Saito H. Two-component signal transducers and MAPK cascades. Trends Biochem Sci,1997,22:172-176
257. Wu T, Chang H, Tan C, Bei W, Chen H. The orphan response regulator RevSC21 controls the attachment of Streptococcus suis serotype-2 to human laryngeal epithelial cells and the expression of virulence genes. FEMS Microbiol Lett,2009, 292:170-181
258. Yang W Z, Yu H J, Jing H Q, Xu J G, Chen Z H, Zhu X P, Wang H, Liu X C, Wang S W, Liu L G, Zu R Q, Luo L Z, Xiang N J, Liu H L, Zhong W J, Liu L, Meng L, Yuan H, Gao Y J, Du H M, Ou Y B, Ye C Y, Jin D, Lv Q, Cui Z G, Huang Y, Zhang S Y, An X D, Huang T, Zhou X Y, Feng L, Pang Q D, Shu Y L, Wang Y. An outbreak of human Streptococcus suis serotype 2 infection presenting with toxic shock syndrome in Sichuan, China. Zhonghua Liu Xing Bing Xue Za Zhi,2006,27:185-191
259. Yarwood J M, McCormick J K, Schlievert P M. Identification of a novel two-component regulatory system that acts in global regulation of virulence factors of Staphylococcus aureus. J Bacteriol,2001,183:1113-1123
260. Yu H, Jing H, Chen Z, Zheng H, Zhu X, Wang H, Wang S, Liu L, Zu R, Luo L, Xiang N, Liu H, Liu X, Shu Y, Lee S, Chuang S, Wang Y, Xu J, Yang W, China SSG. Human Streptococcus suis outbreak, Sichuan, China. Emerg Infect Dis,2006, 12:914-920
261. Zahner D, Kaminski K, van der Linden M, Mascher T, Merai M, Hakenbeck R. The ciaR/ciaH regulatory network of Streptococcus pneumoniae. J Mol Microbiol Biotechnol,2002,4:211-216
262. Zhu H, He J, Jing H B, Wang Z Q, Duan Q. Isolation and identification of Streptococcus suis serotype 2 from sick-pig samples of Sichuan province. Wei Sheng Wu Xue Bao,2006,46:635-638